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Summary 
 
Accumulation of amyloid-β peptides (Aβ) in the CNS is an invariant feature of 
the pathophysiology of Alzheimer’s disease (AD), the most common form of 
dementia. Aβ peptides are derived from proteolytic cleavage of the amyloid 
precursor protein (APP) with the β-secretase cleaving at the N terminus and 
the γ-secretase(s) at the C terminus of Aβ peptides.  
Accumulation of Aβ in the brain has a fundamental role in AD-pathology 
including the induction of tau phosphorylation and neurofibrillary tangle 
formation, deficits in synaptic transmission and synaptotoxicity, and leads to 
age-dependent neuronal loss. Given all the above, concentrated effort has 
been focused on the identification of regulatory mechanisms that control APP 
cleavage and are involved in Aβ production, on proteases with the capacity to 
degrade Aβ, as well as on neuroprotective factors. 
A large body of literature indicates that alterations in cholesterol levels affect 
APP metabolism. Moreover, cholesterol is the major lipid constituent of the 
detergent resistant cholesterol-rich membrane domains (DRMs or rafts). The 
functional significance of DRM domains has been shown in cellular trafficking 
and in signaling events. The disorganization of DRM due to low cholesterol 
levels have been described in the hippocampus and cortex of a significant 
number of AD patients. In addition, DRMs are important to restrict APP β-
cleavage and reduce Aβ production in primary neurons in culture. 
Consistently, these alterations also result in diminished activity of the Aβ 
degrading enzyme plasmin, which is normally produced in these domains. 
The majority of studies exploring the biological function of DRMs have been 
based on pharmacological approaches utilizing drugs that diminish cholesterol 
or sphingolipids, or based on modifications of DRM proteins in cultured cells. 
The functions of DRMs in living animals, however, have not yet been shown. It 
is especially not known how changes in cholesterol levels and distribution 
affect DRM dependent functions, such as APP processing in vivo. 
Seladin-1 (the selective Alzheimer’s disease indicator-1), encoded by a single 
gene (DHCR24) on chromosome 1, is an evolutionary conserved gene whose 
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product catalyzes the reduction of the ∆24 double bond of sterol intermediates 
leading to cholesterol production. It was shown that seladin-1 levels are lower 
in affected neurons in AD, suggesting that seladin-1 levels may influence the 
selective vulnerability of neurons in AD. Overexpression of seladin-1 in vitro 
protected cells from apoptosis induced by oxidative stress and high 
expression of endogenous seladin-1 was associated with resistance against 
Aβ-induced toxicity. Moreover, functional expression of seladin-1 resulted in 
the inhibition of caspase 3 activation after either Aβ-mediated toxicity or 
oxidative stress and protected the cells from apoptotic cell death. Deficiency in 
the Dhcr24 gene causes a severe autosomal recessive disorder characterized 
by elevated levels of the cholesterol precursor desmosterol in plasma. 
Seladin-1 knock-out mice are viable, although almost no cholesterol was 
detected in plasma and tissue of these animals.  
This study gives insight into the role of seladin-1 in neuroprotection, regulation 
of cholesterol levels and cholesterol-mediated functions in vitro and in vivo. 
We show that seladin-1 expression modulates APP processing and Aβ 
generation in vivo. We substantiated the anti-apoptotic function of seladin-1 in 
human neuroblastoma cells and show for the first time that elevated seladin-1 
expression increases the levels of cellular and membrane cholesterol and 
therefore affects the distribution and function of rafts in these cells. 
Furthermore, we demonstrate that the overexpression of seladin-1 leads to 
reduced amyloidogenic APP processing and decreased generation of the Aβ 
peptide. In contrast, decreased seladin-1 expression in mouse brain resulted 
in lower levels of cellular and membrane cholesterol and elevated 
concentrations of the cholesterol presursor desmosterol. A significant increase 
of Aβ40 and Aβ42 was observed in brains of seladin-1 deficient mice 
overexpressing the human APP carrying the Swedish mutation when 
compared to littermates with a normal seladin-1 expression. The findings that 
low expression of seladin-1 parallele a reduction in brain cholesterol levels 
strengthen the notion that brain cholesterol loss participates in the 
pathogenesis of AD. Because of its role in cholesterol synthesis and 
neuroprotection, increasing seladin-1 activity in CNS neurons may therefore 
represent a putative therapeutical target for AD treatment. 
 
  7 
Z
U
S
A
M
M
E
N
F
A
S
S
U
N
G
Zusammenfassung 
Die Alzheimer Krankheit ist eine der häufigsten Formen von seniler Demenz 
bei älteren Menschen. Sie ist durch den Verlust von Gedächtnis und anderen 
kognitiven Funktionen gekennzeichnet, welcher wiederum auf den Verfall von 
Nervenzellen zurückzuführen ist. Bisher gibt es noch keine eindeutige 
Erklärung für diesen zahlreichen Zerfall der Neurone, doch scheint unter 
anderem die vermehrte Ablagerung von abnormalen Proteinen die Ursache 
hierfür zu sein. Diese bestehen teilweise aus extra- und intrazellulärem β-
amyloid (Aβ), dem Spaltprodukt des Vorläuferproteins (APP). Aβ reichert sich 
im Krankheitsfall zu Plaques an und ist schädlich für die Nervenzellen. Zum 
anderen finden sich in Gehirnen von Alzheimer Patienten intrazelluläre 
Anreicherungen von so genannten „tangles“, das sind hyperphosphorylierte 
Formen des Zellgerüst-assoziierten Proteins Tau. 
In ca. 10% der Alzheimer Fälle wird die Krankheit durch Genveränderungen 
ausgelöst. In dieser familiären Form der Erkrankung treten die klinischen 
Zeichen und neuropathologischen Veränderungen bereits in jüngeren Jahren 
auf. Der wichtigste Risikofaktor für die spontane Form der Alzheimer 
Krankheit ist eine Genvariante des Proteins Apolipoprotein E, welches am 
Transport von Cholesterin im Blut beteiligt ist. Tierstudien legen ebenfalls 
einen Zusammenhang zwischen hoher Cholesterin-Aufnahme und der 
Entwicklung einer Alzheimer Krankheit nahe. Cholesterin ist ein wichtiger 
Baustein von Zellmembranen. Innerhalb der Membran existieren flossartige 
Strukturen, die sogenannten „rafts“, welche von Cholesterin 
zusammengehalten werden. Diese „rafts“ spielen eine wichtige Rolle bei der 
Übermittlung von Signalen und werden ausserdem mit der Prozessierung von 
APP in Zusammenhang gebracht.  
Seladin-1 ist ein Protein aus der Familie der Flavin-Adenin-Dinukleotid-
abhängigen Oxidoreduktasen und ein wesentliches Enzym im 
Cholesterinstoffwechsel. Seladin-1 wurde vor einigen Jahren im Rahmen 
einer Studie entdeckt, in welcher erkrankte Hirnregionen von Alzheimer 
Patienten mit gesunden Bereichen verglichen wurden. In den kranken 
Regionen ist das Expressionsniveau von Seladin-1 signifikant geringer, 
weshalb es auch der selektive Alzheimer’s Disease Indikator -1 genannt wird.  
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In der vorliegenden Studie wurde die Rolle von Seladin-1 während des 
programmierten Zelltods (Apoptose) und bezüglich des 
Cholesterinstoffwechsels näher untersucht. Wir konnten zeigen, dass die 
Überexpression von Seladin-1 Zellen resistenter gegen Apoptose macht und 
zu einer Zunahme der Cholesterinkonzentration in der Membran führt. 
Letzteres resultierte in einer massgeblichen Beeinflussung der 
Zusammensetzung und Funktion der „rafts“. Ebenso konnten wir darlegen, 
dass höhere Seladin-1- und Cholesterinspiegel die Prozessierung von APP 
und damit die Aβ Produktion hemmen. Im Gegensatz dazu zeigten Seladin-1 
defiziente Mäuse geringere Cholesterinkonzentrationen in der Membran und 
eine erhöhte Aβ Bildung.  
Diese Ergebnisse zeigen zum ersten Mal, dass die Modifizierung der Seladin-
1 Expression, und damit einer endogenen Komponente, zu einer 
Veränderung der Cholesterinkonzentration führen kann und dass Seladin-1 
ein essentieller Regulator der Zusammensetzung und der Funktion von „rafts“ 
ist. Das Resultat, dass die Erhöhung von Seladin-1 die Aβ Bildung reduziert, 
weist Seladin-1 als möglichen therapeutischen Angriffspunkt in der Alzheimer 
Behandlung aus. 
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Introduction 
 
Alzheimer’s disease 
Aging is one of the most significant risk factors for neurological disorders 
including Alzheimer’s disease (AD), the most common form of dementia. AD 
was first described by the German physician Alois Alzheimer in 1907 and is 
characterized by progressive atrophy and loss of neurons resulting in 
cognitive deficits, confusion and dementia, culminating in childlike 
helplessness and death. The two major pathological hallmarks of the disease 
are amyloid plaques, which are composed primarily of insoluble β-amyloid 
fibrils, and neurofibrillary tangles (NFTs), consisting of paired helical filaments 
(PHF) of hyperphosphorylated Tau. According to a statistical investigation of 
the World Health Organization, AD and other dementias have an overall 
prevalence of about 5 % for men and 6 % for women aged above 60 years.  
 
Amyloid percursor protein (APP) and Aβ-peptide generation 
APP is a polypeptide that is cotranslationally translocated into the 
endoplasmic reticulum via its signal peptide and then posttranslationally 
modified through the secretory pathway. It is a ubiquitously expressed type I 
integral membrane protein with a large extra- and a short intracellular 
domain6. The role of APP remains unclear. Both during and after the 
trafficking of APP through the secretory pathway, it can undergo a variety of 
proteolytic cleavages to release secreted derivatives into the lumen and the 
extracellular space. The first proteolytic cleavage identified, made by an α-
secretase, occurs 16 amino acids NH2-terminal to the single transmembrane 
domain of APP6. This processing results in the release of the large soluble 
ectodomain fragment (α-APPs) into the lumen/extracellular space and 
retention of an 83-residue COOH-terminal fragment (CTF) in the membrane. 
Alternatively, some APP molecules not subjected to α-secretase cleavage can 
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be cleaved by an activity designated β-secretase, which principally cuts 16 
residues NH2 terminal to the α-cleavage site, generating a slightly smaller 
ectodomain derivative (β-APPs)7 and retaining a 99-residue CTF (C99) in the 
membrane that begins at residue 1 of the Aβ region8. It was assumed that Aβ 
generation was a pathological event, because the cleavage of the C99 
fragment resulting from the γ-secretase activity appeared to occur in the 
middle of the transmembrane domain. Furthermore it was assumed that this 
would require the release of C99 from the membrane, for example, as a result 
of some pre-existing membrane injury that allowed access to a soluble 
protease. However, Aβ was shown to be constitutively released from cells 
under entirely normal cellular conditions7,9-11. Similarly, a peptide fragment 
designated p3 was discovered to be produced by the sequential actions of the 
α- and γ-secretases10,12. These findings indicate that Aβ production is a 
normal metabolic event, and indeed, the peptide can be detected in both 
--α secretase
C
APP
AICD
sAPP -α
α
β
γ
N
C
Aβ
AICD
sAPP -β
p3
secretaseγβ secretase--γ secretase
Processing of APP  
Aβ is derived by sequential proteolytic cleavages: APP is either cleaved by an α-secreatase 
followed a γ-secretases resulting in the nonamyloidogenic P3 peptide, an N-terminal soluble 
APP α and an APP intracellular C-terminal domain (AICD), or by a β-secreatase prior to the 
γ-secretase, producing the amyloidogenic Aβ and soluble APPβ.  
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cerebrospinal fluid and plasma in healthy subjects throughout life7,11. 
Cleavage by the γ-secretase can occur at position 40 or 42 of the Aβ 
sequence and gives rise to Aβ40 or Aβ42, the latter having a higher tendency to 
aggregate and thus being more amyloidogenic13. The γ-secretase is a 
multiprotein complex, which includes presenilin1 (PS1), presenilin2 (PEN-2)14, 
APH-1, and nicastrin15. The γ-secretase complex cleaves several type I 
transmembrane proteins, such as Notch 116, ErbB417, N- and E-Cadherins 18 
following a regulated intramembrane proteolysis process19. The shorter form, 
Aβ40, accounts for about 90% of the Aβ in AD brains. This proportion varies 
depending on the different mutations in presenilins and APP, influencing 
among others the activity of the secretases. In familial cases of AD (FAD) 
such mutations are believed to cause AD by increasing Aβ42 production, or by 
increasing the ratio of Aβ42 to Aβ40 peptides.20,21 
 
 
Aβ peptide degrading enzymes 
The accumulation and polymerization of Aβ are considered to be 
pathologically important in AD22. This hypothesis is supported by the 
impairment exerted by Aβ on synaptic trasmission and neuronal viability23. 
Numerous studies show the toxicity of Aβ-peptide but the mechanisms how 
this peptide initiates the cascade of death is not known to the last detail. 
Whereas higher production of Aβ leads to familial forms of AD (FAD), no 
indications of increased Aβ generation is observed in sporadic forms of the 
disease, that constitudes the majority (up to 95%) of AD cases24. Therefore, a 
reduced degradation of the Aβ peptide can lead to its accumulation to AD. 
Various proteases have been implicated in Aβ degradation, including 
neprilysin (NEP), a membrane-anchored zinc endopeptidase, involved in 
digestion of biologically active small peptides such as substance P, 
enkephalines and somatostatin, and insulin-degrading enzyme (IDE)25, a thiol 
metallo-endopeptidase that was discovered based on its activity to degrade 
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insulin. Whereas IDE exclusively degrades soluble monomeric but not 
oligomeric Aβ species, NEP is capable of degrading monomeric and 
oligomeric Aβ. NEP is the rate limiting enzyme for Aβ degradation in vivo and 
its expression is downregulated in AD brains. Another important protease 
involved in Aβ degradation is the serin protease plasmin26. Plasmin activity is 
regulated by plasminogen-activators and inhibitors as well as plasminogen 
activator inhibitors and plasmin inhibitors27. In addition, plasmin generation is 
dependent on the binding of plasminogen to the plasma membrane. 
Plasminogen activators (PAs) are serine proteases, the main function of which 
is to activate plasminogen into plasmin. There are two types of mammalian 
plasminogen activators: tissue-type (tPA) and urokinase-type (uPA)28. tPA is 
expressed in various regions of the mouse brain, including the hippocampus, 
amygdala, cerebellum and hypothalamus29, where it participates in both 
normal and pathological events30. In particular, tPA is highly expressed in the 
hippocampus, a region important for learning and memory and often involved 
in AD pathology. Furthermore, uPA and tPA are also involved in a critical step 
in the excitotoxin-induced neurodegeneration31,32. tPA acts by two known 
pathways, a proteolytic and a  non-proteolytic. The proteolytic one proceeds 
via its ability to convert plasminogen into plasmin33,34. Plasmin is involved in 
neuronal death, degradating the extra-cellular matrix (ECM) and preparing a 
gradient of chemoattractants for microglia34 and contributes to neurite 
outgrowth by processing the proteoglycans in the ECM. Recent studies have 
shown that tPA potentiates signaling mediated by glutamatergic receptors 
through  proteolytic regulation of N-methyl- D-aspartate (NMDA) receptors 
and thus increasing the influx of calcium35. In the nonproteolytic pathway, tPA 
stimulates a cell-surface receptor on microglia, resulting in microglial 
activation. Once activated after neuronal injury, microglia contribute to 
neurodegeneration36 and are associated with several diseases, like AD37 and 
stroke 38. It is evident that Aβ degrading enzymes play an important role in AD 
– these proteases are logical targets for drugs attenuating AD and are being 
considered as possible targets for retarding AD pathogenesis.  
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Neurofibrillary tangles and the microtubule-associated protein tau 
The cytoskeleton plays a major role in establishing and maintaining the 
regional specialization within neurons. Microtubules are responsible for 
neurite extension and serve as the tracks for transport within the cells. 
Microtubule-associated proteins play an important role in the assembly of 
microtubules, in cross-linking of microtubules to each other and to other 
filaments. Tau belongs to the family of microtubule-associated proteins and it 
is involved in microtubule assembly and stabilization. In humans, tau is mainly 
found in neurons39. It is encoded by one single gene on chromosome 17q21 
which consists of 16 exons40 that are alternatively spliced generating six tau 
isoforms, which differ by the presence of either three (3R-tau) or four (4R-tau) 
carboxy-terminal repeats41,42. Tau can be phosphorylated by different kinases 
like GSK-β and at least thirty different phosphorylation sites have been 
described using phosphorylation-dependent antibodies. Tau 
hyperphosphorylation precedes neurodegeneration because it abolishes its 
biological function to bind microtubules and promotes microtubule assembly. 
To regulate the activity and binding property, tau is dephosphorylated by 
phosphatases, in neurons particularly by protein phosphatase 2A (PP2A), a 
holo-enzyme found predominatly in the brain43.  
Hyperphosphorylation of tau is believed to be an early event in the pathway 
that leads from soluble to insoluble and filamentous tau protein, that has the 
tendency to aggregate to paired helical filaments (PHF). Neurofibrillary 
tangles (NFTs), the filamentous intraneuronal inclusions which, together with 
amyloid plaques, define the pathology of AD are composed of PHFs and 
straight filaments (SFs) and their spreading thoughout the brain cortex 
correlates with the degree of neuronal loss44. Several other 
neurodegenerative disorders characterized by the presence of filaments 
composed of hyperphosphorylated tau in glial and neuronal cells, 
degenerating neurites and Pick bodies are known, collectively referred to as 
tauopathies. The filamentous Tau aggregates are consistently found in AD, 
corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), 
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Pick’s disease (PiD) and frontotemporal dementia, including fronto-temporal 
dementia with Parkinsonism linked to chromosome 17 (FTDP-17)45  
 
The amyloid cascade hypothesis  
Since the first description of the disease by Alois Alzheimer, Aβ plaques and 
NFTs have been the defining neuropathological hallmarks of AD, but still 
today their pathophysiological relation remains unclear. According to the 
amyloid cascade hypothesis, accumulation of Aβ in the brain parenchyma is 
the first step in the development of the disease46. Crossbreeding of a mouse 
Altereted APP
processing
Increased Aβ42
production 
Oligomerization and
depositon of Aβ as plaques
Neurotoxicity
of oligo and protofirillar Aβ
Infalmmatory response
activation of microglia and astrocytes
Neuronal injury
Progressive oxidative injury
and altered ionic homeostasis
Changes in intracellular signaling
(kinase and phosphatase)
Tau hyperphosphorylation and
tangle formation
Neuronal death dementia
The amyloid cascade hypothesis: in AD, an aberrant APP metabolism leads to an 
increase in Aβ levels and, subsequently, Aβ aggregation and plaque formation. Oxidative 
stress, gliosis and neurotoxic properties of Aβ induce synaptic loss and 
neurodegeneration, and according to the hypothesis, Aβ is also the trigger for tau 
pathology in AD. 
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line expressing a tau mutation associated with FTDP-17 with mice expressing 
a mutated variant of APP that causes AD in humans led to a dramatic 
increase in NFT formation in these mice47. Stereotaxic injection of Aβ42 fibrils 
into the brains of another transgenic mouse line expressing the same tau 
mutation caused a fivefold increase in the numbers of NFTs in cell bodies 
within the amygdala from where neurons project to the injection sites 48. 
Although these experiments failed to dissect a distinct pathway by which Aβ 
induces NFT formation and neuronal death, they support the evidence that 
aggregation of Aβ is an initial event in AD pathogenesis and that other 
features of the disease, including hyperphosphorylation of tau and 
subsequent tangle formation, result from an imbalance between production 
and clearance of Aβ49. For Aβ-induced neurotoxicity, several mechanisms 
have been proposed including oxidative stress, free-radical formation, 
disrupted calcium homoeostasis, induction of apoptosis, neuritic damage, 
chronic inflammation and formation of amyloid pores8,50. Another potential 
mechanism involves the interaction of Aβ with cell-surface receptors and APP 
itself, resulting in inhibition or aberrant activation of signal transduction 
pathways. 
Viable mouse models for Alzheimer’s disease 
To investigate the pathological process that underly AD, many animal models 
have been developed. These models are based on the knowledge of proteins 
involved in the pathology of the disease in humans. Rare autosomal dominant 
mutations causing early familial forms of AD were described for APP and the 
presenilin1 (PS1) and 2 (PEN2) genes. Several transgenic mouse-lines 
overexpressing human APP or one of the FAD-linked APP mutations have 
been generated, exhibiting an AD-like phenotype51-53. For the overexpression 
of the transgenes, different promotors were shown to drive high expression in 
the brain (i.e. the Thy1.2 promotor in brain neurons or the PrP promotor more 
ubiquitously in the CNS). Overexpression of human APP cDNA containing two 
mutations immediatly before the Aβ sequence (K670M/N671L), first 
discovered in a FAD case in a familiy from Sweden - further referred as the 
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Swedish mutation (Sw) – revealed increased Aβ generation by enhanced β-
secretase cleavage. These SwAPP-mice develop the first Aβ deposits as 
early as 6 months after birth in the cerebral cortex and exhibit inflammatory 
reactions like astrogliosis and microgliosis, which are thought to play a key 
role in the pathogenesis of AD54. Double transgenic mice co-expressing the 
M146L presenilin 1 (PS1) and K670N/M671L, SwAPP mutations exhibit an 
earlier Aβ deposition and more profound impairment of working memory and 
learning than single SwAPP mutant mice21. Even though these animal models 
mimic the Aβ related pathology of AD, none of them develop an AD-like tau 
pathology nor exhibit any neurofibrillary tangles or threads. Therefore, animal 
models of the tau pathology were generated by overexpressing wildtype 
human tau in murine neurons55. In this model, transgenic 
hyperphosphorylated tau was present in nerve cell bodies, axons and 
dendrites, but no obvious neurolopathological phenotype or neurofibrillary 
tangles were observed56. The subsequent use of stronger promoters to drive 
transgene expression resulted in a more pronounced phenotype. In addition 
to numerous abnormal tau-immunoreactive nerve cell bodies and dendrites, 
large numbers of pathologically enlarged axons were detected57,58. Tau 
protein extracted from transgenic brain and spinal cord became more 
insoluble with increasing age, whereas NFTs were only found in very aged 
mice. Mice with expression of mutated P301L tau, a mutation leading to a 
higher state of tau phosphorylation, showed motor and behavioural deficits 
and an age- and gene-dose-dependent development of NFTs59. Crossing of 
these mice with mice overexpressing SwAPP gave rise to double mutants with 
substantial neurofibrillary tangle pathology47. Moreover, injection of Aβ42 fibrils 
into the brains of these mice caused fivefold increases in the number of NFTs 
in cell bodies within the amygdala from where neurons project to the injection 
sites48. As the hyperphosphorylation of tau abolishes its ability to bind to the 
microtubules and promote their assembly, the function of protein 
phosphatases that might restore the physiological function of tau has also 
been investigated using different animal models. An attempt to examine the 
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function of PP2A in a mouse model by using a knockout technique has been 
unsuccessful, because the selective knock-out of this enzyme was lethal60. 
This problem could be circumvented by expression of a dominant negative 
mutant form of the catalytic subunit Cα of PP2A, which gave rise to mice with 
a substantially reduced PP2A activity and tau hyperphosphorylation61. 
 
Apoptosis in central nervous system 
Mature neurons are the longest living among mammalian cells. In contrast, 
immature neurons die in large numbers during development. The induction of 
developmental cell death is a highly regulated process that is dependent on a 
variety of trophic factors and can be suppressed by various extracellular 
stimuli. A chemical or electrical feedback from the neighboring tissue is 
important for neuronal survival62. Developing neurons compete for the 
restricted trophic factors provided and only such neurons, which complete 
successfully their connections have a higher probability for survival. Neuronal 
apoptosis often occurs via an intrinsic apoptotic cascade triggered by the 
translocation of Bax, a pro-apoptotic Bcl-2 family member, to mitochondria. In 
response to signals generated by Bcl-2 family members, such as Bim and Bid, 
Bax oligomerizes at the outer mitochondrial membrane and forms a pore that 
releases cytochrome c from the mitochondria63. Cytosolic cytochrome c then 
interacts with Apaf-1 and pro-caspase-9 to form a functional apoptosome that 
ultimately activates downstream executioner caspases like caspase-364. The 
Bax-dependent mitochondrial pathway is often used to model apoptosis 65-67. 
Numerous caspases which are cysteine aspartate-specific protease play a 
major role in neuronal apoptosis68. Caspase-8 and caspase-10 contain death-
effector domains which bind to the intracellular domain of receptors like CD95 
(Fas) and tumor necrosis factor (TNF) receptors and initiate programmed cell 
death. Caspases, like caspase-1,-2,-4,-5, which contain a caspase activating 
recruitment domain (CARD) are mostly activated by the complex caspase9-
cytochromc-Apaf1. Caspases that have a short active pro domain like 
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caspase-3 and -6 are activated by all caspase pathways. Observations that 
caspases-11 and -12 can be activated in particular pathological terms are of 
great interest to therapeutic approaches against cellular degeneration69,70. 
Examining several knock-out mice for caspases like caspase-3,-9 and for 
Apaf-1 show the importance of caspases in the context of neuronal death. 
 
Neuronal survival and cell death 
The survival of developing immature neurons depends on the availability of 
neurotrophic factors. Neurotrophins generally activate and ligate the tyrosine 
kinase receptors (TrkA, TrkB and TrkC) which are cell-surface receptors with 
intrinsic tyrosine kinase activity. The receptors can autophosphorylate71. For 
instance, the binding of nerve growth factor (NGF) to TrkA leads to the 
phosphorylation of several tyrosine residues within the cytoplasmic tail of 
TrkA. These phosphotyrosines in turn serve as docking sites for other 
molecules such as phospholipase Cγ, phosphoinositide 3-kinase (PI(3)K)72 
and adaptor proteins such as sonic hedgehog (Shc), coordinate neuronal 
survival. The Akt protein is another important kinase implicated in the 
neuronal death. It is responsible for the inhibition and activation of different 
proteins involved in the survival of the cell. Akt acts in the 
phosphatidylinositide 3’OH kinase (PI(3)K)/c-Akt kinase cascade. c-Jun 
pathway is activated after NGF withdrawal, and blocking this pathway inhibits 
neuronal cell death. The overexpression of PI(3)K or of its downstream 
effector Akt kinase blocks cell death in neurons after NGF withdrawal, even 
though the c-Jun pathway is activated. Stimulation of the PI(3)K pathway is 
sufficient to allow cells to survive in the absence of NGF73 . From three 
isoforms, c-Akt3 is the major one expressed in neurons and its binding to 
phospholipids and proteins supports neuronal survival. Akt phosphorylates 
Bad, a pro-apoptotic protein, and inhibits its activity during deprivation of 
trophic factors. Akt has been shown to affect, directly or indirectly, three 
transcription factor families, forkhead, which transcribes CD95L protein, 
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cAMP-response element-binding protein (CREB) and NF-κB, which are all 
involved in regulating cell survival. It is obvious that Akt is a potent kinase that 
keeps neurons alive in various ways and certainly additional targets of Akt will 
be identified. Neurotrophins can not only activate PI(3)K and Akt, but also they 
can activate Trk receptors which in turn trigger small GTP–binding protein Ras 
and the downstream MAP kinase cascade, which includes Raf, MAP 
kinase/ERK kinase (MEK) and the extracellular signal regulated protein kinase 
(ERK)74. The involvement of MAP in the neuronal survival is at least partially 
linked to the activation of the ribosomal S6 kinase (RSK) family members. 
Together with Akt, these kinases are responsible for the the phosphorylation 
of Bad and therefore for its inactivation. RSK also activates CREB 
transcription factors. CREB activates in turn the transcription of bcl-2, and, 
therefore, can directly stimulate cell survival. Neurotrophins suppress 
apoptosis via activation of different inhibitors of death factors. Deprivation of 
growth factors leads to a decrease of kinase activities like MAP kinase and 
PI(3)K and to reduced glucose uptake and protein synthesis. In parallel, 
several other kinases are upregulated, c-Jun amino-terminal kinase (JNK) and 
p38 MAP kinase are the two most common in this context. It is shown that a 
permanent generation of pro-apoptotic proteins is required66. Understanding 
the role of neurotrophic factors in the complex events of apoptosis is 
necessary to accumulate enough knowledge to design drugs against 
neurodegeneration, as it occurs in AD and Parkinson’s disease (PD).  
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Neuronal cell death in Alzheimer’s disease 
The neuronal degeneration in AD can be described as an apoptotic event, 
although the underlying process is not known to the last detail. Compared to 
the massive and progressive neuronal loss in brains of AD patients, only few 
neurons were detected in apoptotic stages in post-mortem analysis. These 
findings suggest that apoptosis may not be the only process causing neuronal 
death in AD75,76. It is generally believed that Aβ production and aggregation is 
responsible for disease progression, as high Aβ levels are toxic to the brain77, 
but the question how this accumulation of the peptide causes cognitive 
decline is still unanswered.  It has been shown that Aβ peptides actually kill 
neuronal cells in vitro, induce oxidative stress and increase the intracellular 
concentration of Ca2+-ions 78,79. The interaction between Aβ and neuronal 
receptors like p75 neurotrophin receptor, a tumor necrosis factor receptor 
(TNF-R) or receptor for advanced glycation endproducts (RAGE) are shown to 
induce apoptosis in vitro80,81. In support of the notion that in vitro neurotoxicity 
of Aβ is not an artifact, this cytotoxicity is mediated by defined intracellular 
Possible induction of apoptosis by the Aβ peptide in neurons 
Different receptors on the neutonal membrane can be activated by Aβ in different 
manners and consequently induce programmmed cell death through different pathways. 
Aβ can also activate astrocytes, and microglia which in turn activate certain neuronal 
receptors and induce apoptosis. 
 
TNF-R
P75-R
RAGE
?? others
apoptosis
Activation
Aβ
TNFα, IL1β,   other cytokines
TNFα, ROS
TNF-R
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signaling mechanisms, including the destabilization of calcium homeostasis79, 
oxidative stress relevant pathways78, calpain-activated cdk5 pathway82, 
caspase-dependent pathways83 and the c-Jun N-terminal kinase (JNK) 
pathway84. Moreover, neurons with elevated Aβ generation exhibit a higher 
vulnerability to additional toxic stimuli in vivo; in addition, anti-Aβ immune 
therapy reduces Aβ and protects neurons against exitotoxicity. 
 
Cholesterol and other sterols in the CNS 
The cellular needs for cholesterol in the periphery is covered by de novo 
synthesis and by cellular uptake of liproprotein-associated cholesterol from 
the circulation. The blood-brain barrier effectively prevents cholesterol uptake 
from the circulation, and de novo synthesis is responsible for practically all 
cholesterol present in the brain. Cholesterol synthesis and degradation is 
highly regulated in the CNS. Essentially all (99.5%) cholesterol is unesterified, 
and the majority of cholesterol present in the CNS is believed to reside in two 
different pools: one represented by the myelin sheaths (e.g. oligodendroglia) 
and the other by the plasma membranes of astrocytes and neurons85. A 
noteworthy characteristic of myelin is that it contains approximately 70% lipid 
and 30% protein, whereas most other cell membranes are composed of more 
than 70% proteins and 30% lipids. It has been estimated that up to 70% of the 
brain cholesterol is associated with myelin. Cholesterol synthesis in the 
developing mamalian CNS is relatively high, but declines to a very low level in 
adults. This can be explained by an efficient recycling of brain cholesterol. As 
a consequence, brain cholesterol has an extremely long half-life of about 5 
years in humans86. In mammalian brain, cholesterol is synthesized mainly in 
astrocytes, tranlocated to the cell surface by the ATP-Binding Cassette 
Transporter A1 (ABCA1)87 and tranported to the neurons by apolipoprotein E 
(apoE). Although the recycling system seems quite efficient, there are two 
mechanisms known at present for the excretion of cholesterol from the brain 
to maintain the steady state. There is some excretion of apoE-bound 
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cholesterol via the CSF, whereas the precise sites and mechanism of the 
elimination remain to be conclusively established. A quantitatively more 
important mechanism involves conversion of cholesterol to 24OH-cholesterol, 
a reaction catalized by the 24OH-hydroxylase, a brain specific protein 
encoded by the CYP46 gene. This oxysterol is able to traverse the blood-brain 
barrier and has been demonstrated to be a very specific and the most 
important excretion mechanism for cholesterol in the brain88. 24OH-
cholesterol is not only a degradation product of cholesterol but also a 
regulator for the key enzymes in cholesterol transcription and post-
translational events, as well as a precursor for steroid hormones89. All genes 
regulated by sterols contain a sterol-responsive element (SRE) within the 5’-
flanking region. Through the binding of SRE binding proteins (SREBP), sterols 
control the transcription of these genes. Cholesterol is mostly synthetized in 
the endoplasmatic reticulum (ER) and transported to the membrane. A very 
small amount of cholesterol is stored as cholesterol-esters in the brain, 
esterified by ACAT1, a brain specific enzyme. Cholesterol is known to be an 
essential modulator of the physicochemical state and functional activity of 
physiological membranes90 and thus plays an essential role in the regulation 
of synaptic function and cell plasticity91. In the past, decade evidence of a 
possible link between cholesterol and neurodegeneration has accumulated. 
Some of the earliest observations of this link were the recognition of ε4 
isotype apoE as an important risk factor for late-onset Alzheimer’s disease92 
and that hypercholesterolemia was associated with increased brain Aβ 
immunoreactivity in rabbits93. In Niemann-Pick Type C (NPC) disease, an 
autosomal recessive disorder, abnormal intracellular accumulation of 
cholesterol and glycosphingolipids is found, leading to progressive 
neuropathology, neurodegeneration, and premature death. In Smith-Lemli-
Optiz syndrome, a defective 7-dehydrocholesterol-7-reductase leads to the 
abnormal accumulation of 7-dehydrocholesterol, a direct precursor of 
cholesterol. Patients with desmosterolosis have a reduced activity of the 3β-
hydroxy-σ5-steroid-24 reductase, also named seladin-1, leading to the 
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pathological accumulation of desmosterol and to premature death4,94. Several 
in vitro and numerous mouse models have been generated to study the 
different diseases correlated to the pathological changes in cholesterol 
homeastasis and metabolism.  
 
Apolipoprotein E 
Apolipoproteins are lipid carrier molecules. They play an important role in the 
coordination of the metabolism of lipids following peripheral and central 
nervous system injuries95,96. Apolipoprotein E (apoE) in particular is unique 
among apolipoproteins in that it has a special relevance to nervous tissue. 
The 34 kDa glycosylated protein is encoded on chromosome 19 and plays a 
pivotal role in the mobilization and redistribution of cholesterol and 
phospholipid during membrane remodelling associated with synaptic 
plasticity95. Three common alleles are known for apoE, ε2, ε3 and ε4, are 
ApoE
ABCA1
cholesterol
24OH cholesterol
CYP46
elimination
24OH
recycling 
Interactions of astrocytes and neurons in cholesterol homeostasis according to 
Pfrieger and collegues2,3. 
Although neurons are capable of synthesizing cholesterol, it has been suggested that 
neurons rely on delivery of cholesterol from nearby cells such as astrocytes. 
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present in 7%, 78% and 15% of the population, respectively97. ApoE has been 
associated with AD since carriers of the apoE ε4 allele have an enhanced risk 
of developing AD, whereas carriers of ε2 are protected98.  
This apoE effect is explained by its physiological function in lipid clearance, 
which is inversely correlated with Aβ deposition. apoE is found in Aβ plaques 
in AD patients and is correlated with Aβ deposition around blood vessels and 
in the brain parenchym26. Deposition of Aβ is also observed in ε4 allele 
carriers even in the absence of AD causing mutations99. Controversially, co-
expression of APP and the ε4 allele does not lead to a significant variation in 
the production of Aβ in cell culture100. In vitro studies have shown that ε4 
increases fibrillogenesis of Aβ, supporting the hypothesis of a direct role of 
apoE in amyloid deposition101. In apoE knock-out mice crossed with mice 
transgenic for a mutant form of APP, the plaque load is decreased compared 
with single APP transgenic mice. These results indicate that the ApoE ε4 
allele enhances the aggregation and/or decreases the clearance of the Aβ 
peptide in the brain102,103. Furthermore, ε4 may also directly affect nerve cells. 
Primary neurons derived from transgenic mice expressing the ε4 allele show a 
decrease in neuritic outgrowth and maintenance of neurites104. Astrocytes 
provide the brain with apoE, and although  it is mostly considered a lipid 
transport molecule, data suggest that it plays additional roles in the brain 
regulating astrocyte and neuronal function, like, for example, calcium 
homeostasis105. ApoE modulates transmitter release and sequestration and 
enhances the rate of glutamate uptake and prevents excitotoxicity106,107. 
These diverse functions may be due to the variations in the ability of the 
isoforms to transport lipids, bind receptors or influence other cellular functions 
such as cholesterol homeostasis and microtubule stabilization108.  
 
Detergent Resistent Membrane Microdomain (DRM) or Raft 
Most cellular cholesterol resides within plasma membranes, which consist of 
two leaflets that are asymmetric in lipid distribution, electrical charge, fluidity, 
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function and possibly the localization of lipid rafts109-111. Within the plasma 
membane 70%-85% of free cholesterol resides in the cytofacial bilayer leaflet, 
whereas only 15-30% join the exofacial leaflet112. Exofacial cholesterol builds 
up lateral membrane domains such as kinetic pools of lipid rafts111. The 
existence of lipid rafts was postulated more then 10 years ago113. These 
membrane domains were shown to be resistant to Triton X-100, a nonionic 
detergent, and are therefore also named Detergent Resistant Membrane-
domains (DRMs). DRMs are specialized plasma membrane microdomains 
highly enriched in glycosphingolipids and multiple membrane proteins114. 
There is strong evidence to suggest that cholesterol condenses the packing of 
sphingolipid molecules and thus cholesterol-sphingolipid microdomains form a 
separate lipid-ordered phase in the exofacial leaflet115. Functionally, lipid rafts 
are thought to be involved in intracellular trafficking of proteins and lipids, 
secretory and endocytic pathways, as well as in cell-surface proteolysis and 
signal transduction pathways115. Extracellular ligands can initiate DRM 
assembly which in turn can influence strength, duration and quality of 
intracellular signaling. For example, in neurons, the signal transduction is, 
among others, determined by GAP-43 like proteins (e.g. growth-associated 
protein-43 (GAP43), cytoskeleton associated protein of MW23kDa (CAP23), 
myristoylated Ala-rich C-kinase substrate (MARCKS) and dependent of lipid 
rafts116. DRMs are believed to steer efficiency and reliability of extracellular 
signals by concentrating specific proteins, like flotilin 1, in special regions of 
plasma membranes. Other important raft components are sphingolipids like 
sphingomyelin and the ganglioside GM1. Sphingomyelin is a major source of 
ceramides, lipid mediators that are generated when sphingomyelin is cleaved 
by sphingomyelinases. Sphingomyelinases are activated by inflammatory 
cytokines117 and oxidative stress in vivo 118. The ganglioside GM1 was shown 
to bind to the Aβ peptide and perhaps change the latter’s conformation119. 
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Seladin-1  
Seladin-1 shares homologies to a family of flavin-adenine-dinucleotide-
dependent oxidoreductases and is the human homologue of the 
Diminuto/Dwarf1 gene, described in plants (i.e Arabidopsis thaliana) and in 
Caenorhabditis elegans120. In plants, Diminuto/Dwarf1 is required for the 
synthesis of brassinosteroids, which are plant sterols essential for normal 
growth and development121,122. In humans, the seladin-1 (the selective 
Alzheimer’s disease indicator- 1) mRNA has been found to be downregulated 
in brain neurons affected in AD, suggesting that seladin-1 levels may 
influence the selective vulnerability of neurons in this disease5. Greeve and 
colleagues showed that overexpression of seladin-1 in human H4 
neuroglioma cells protected cells from apoptosis induced by oxidative stress, 
and high expression of endogenous seladin-1 was associated with resistance 
N-MEPAVSLAVCALLFLLWVRLKGLEFVLIHQRWVFVCLFLLPLSLIFDIYYYVRAWVVFKLSSAPRLHEQRVRDIQKQ
 
VREWKEQGSKTFMCTGRPGWLTVSLRVGKYKKTHKNIMINLMDILEVDTKKQIVRVEPLVTMGQVTALLTSIGWTLP
 
VLPELDDLTVGGLIMGTGIESSSHKYGLFQHICTAYELVLADGSFVRCTPSENSDLFY PAV WSCGTLGFLVAAEIRIIP
 
AKYVKLRFEPVRGLEAICAKFTHESQRQENHFVEGLLYSLDEAVIMTGVMTDEAEPSKLNSIGNYYKPWFFKHVENY
 
LKTNREGLEYIPLRHYYHRHTRSIFWELQDIIPFGNNPIFRYLFGWMVPPKISLLKLTQGETLRKLYEQHHVVQDML 
 
VPMKCLQQALHTFQNDIHVYPIWLCPFILPSQPGLVHPKGNEAELYIDIGAYGEPRVKHFEARSCMRQLEKFVRSV 
 
HGFQMLYADCYMNREEFWEMFDGSLYHKLREKLGCQDAFPEVYDKICKAARH-C 
Seladin-1 aminoacids sequence 
red  animoacids homologe to mdm2 binding site to p531 
green   animoacids homologe to p53 binding site to mdm21 
blue  mutations leading to desmosterolosis in human4 
black italic caspase cleavage sites5 
yellow box flavin-adenin-dinucleotide (FAD) binding site homologous region5 
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against Aβ-induced toxicity. Moreover, seladin-1 was linked to tau-related 
neuronal degeneration in AD, showing a close inverse correlation between the 
seladin-1 expression level and the presence of neurofibrillary tangles, neuritic 
plaques and paired helical filaments in temporal cortices of AD cases when 
compared to non-demented subjects123. The function of seladin-1, encoded by 
a single gene (DHCR24) on chromosome 1, was investigated in 1979 using 
radioactive acetates. Seladin-1 was shown to catalyze the reduction of the 
∆24 double bond of lanosterol and other obligatory sterol intermediates 
leading to the production of cholesterol124. Deficiency in the Dhcr24 gene 
causes a severe autosomal recessive disorder characterized by elevated 
levels of the cholesterol precursor desmosterol in plasma of the patients 
tested4,125. In tumors seladin-1 expression is elevated, suggesting a role of 
seladin-1 in the suppression of apoptosis126. Seladin-1 knock-out mice are 
viable, even though plasma and tissue of these animals containe almost no 
cholesterol, and desmosterol was shown to account for 99% of all sterols94. 
Homozygous knock-out pups were born at a lower than predicted Mendelian 
frequency, indicative of some prenatal death and were about 25% smaller in 
size. This relatively mild phenotype contrasts dramatically with the severe 
abnormalties observed in patients with desmosterolosis. This discrepancy 
may be due to the fact that maternal cholesterol is not available during human 
embryogenesis127, as it is in mice. Recent findings give evidence of an 
interaction between seladin-1 and the tumor suppressor protein p531. 
Following oncogenic and oxidative stress, seladin-1 binds to p53 amino 
terminus and displaces E3 ubiquitin ligase Mdm2 from p53, thus resulting in 
p53 accumulation, suggesting an unanticipated role for Seladin-1 in 
integrating cellular response to oncogenic and oxidative stress1. 
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Postulated functions of seladin-1
Stress induced by reactive oxigen species (ROS) or other similar stress factors induces the upregulation of seladin-1, 
which inhibits the ubiquitination of p53 and its degradation. Under Aβ stress, seladin-1 can inhibit caspase-3 and -6 . The 
second function is related to the reductase property of seladin-1, which enzymatically reduce desmosterol to cholesterol. 
Cholesterol in turn regulates DRM in composition and function.
DRM 
-composition 
-function
cholesterolp53
mdm2
growth arrest
/senescence
ROS, stress inducers no particular stress
Wu et al., 2004
Crameri et al., 2005
caspases-3 and -6
Greeve et al., 2000
Waterham et al., 2001
desmosterol
seladin-1
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Methods 
 
Molecular methods  
Restriction analyses  
The plasmid DNA was analysed using type II restriction endonucleases. 
These restriction enzymes recognize palindromic sequences within the DNA. 
Digestions were performed in 1x cleavage buffer by addition of the restriction 
endonuclease to the DNA and incubation at 37°C for at least 1 hour. The 
resulting DNA fragments were analysed by agarose gel electrophoresis. 
 
Rapid ligation kit 
The ligations were performed in a volume of 20µl for 20 minutes at room 
temperature. DNA was purified from an agarose gel slice using the Qiagen gel 
extraction kit (Qiagen). Quantitative agarose gel analysis was used to 
estimate the amount of DNA fragments. 200ng of DNA were diluted in 8µl 
H2O, 2µl of 5x dilution buffer, 10µl T4 ligation buffer and 1µl T4 ligase, 
according to the manufacturer’s protocol (Roche). 
 
Preparation and transformation of chemically competent cells  
To transform DNA into E. coli the cell membranes have to be porous. This can 
be achieved by treating the cells with Ca2+. The addition of DNA leads to the 
formation of DNA-Ca2+ complexes, that enter the cells following a short heat-
shock.  
To generate chemically competent bacteria, cultures of DH5α or XL1Blue 
cells were grown in LB-medium at 37°C overnight and harvesterd at an 
OD600nm of 0.375. The cells were pelleted by centrifugation at 4,000g at 4°C 
for 15 minutes, resuspended in 10 ml of a 0.1 M CaCl2 solution and kept on 
ice for 1 hour. Cells were collected by centrifugation at 4,000g at 4°C, 
resuspended in 0.1 M CaCl2, 0.02 M MgCl2, and 15% glycerol. Aliquots of 
competent cells were immediately frozen in liquid nitrogen and stored at –
80°C. 
 
  30 
M
E
T
H
O
D
S
To transform cells, diluted plasmid DNA or an aliquot of a ligation reaction 
were added to 100µl competent E. coli and incubated on ice for 20 minutes. 
Following a heat shock for 90 seconds at 42°C the cells were chilled on ice for 
one additional minute. After adding 1ml LB-medium, the cells were incubated 
on a shaker for 1 hour at 37°C. Cells were plated on LB-agarose plates 
containing the appropriate antibiotics. 
 
Agarose gel electrophoresis  
To analyze or isolate DNA fragments or PCR products these were separated 
by agarose gel electrophoresis. Due to the negatively charged phosphate 
groups in the backbone of nucleic acids, DNA migrates towards the positive 
anode when exposed to an electric field. The migration of linear DNA 
fragments depends mainly on their size. Using ethidium bromide (Sigma), 
which intercalates in the major groove of the DNA and allows visualization 
under UV-light, the length of DNA fragments can be determined by 
comparison with a DNA ladder marker. 
 
Gel extraction 
DNA fragments to be used for ligations, transformations or transfections were 
purified from the agarose slices by the Qiagen gel extration kit according to 
the company’s protocol (Qiagen). 
 
DNA dephosphorylation  
In order to prevent self-ligation of the vector, alkaline phosphatase was used 
to remove terminal 5’-phosphate groups before using the plasmid vector DNA 
in a ligation reaction. Calf intestinal phosphatase (CIP) was used according to 
the manufacturer’s instructions (Promega). 
 
Preparation of plasmid DNA  
The principle of plasmid isolation from E. coli is based on alkaline lysis of the 
cells in combination with the anionic detergent SDS128 that breaks down the 
cell walls and denatures the proteins as well as genomic DNA. In contrast, the 
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strands of closed, much smaller, circular plasmid DNA stay in solution and 
can be recovered from the supernatant. Plasmid DNA was isolated from small 
scale (1-2ml), intermediate scale (20-50ml) and large scale (500ml) bacterial 
cultures using QIAGEN plasmid purification protocols. Briefly, after a modified 
alkaline lysis procedure negatively charged phosphates of the DNA backbone 
are bound to an anion-exchange resin (QIAGEN) and plasmid DNA can be 
purified from RNA and proteins. To avoid a possible contamination of DNA 
with bacterial endotoxins, DNA fragments that were planned to be injected 
into oocytes for generation of trangenic mice were purified using the QIAGEN 
EndoFree Maxi kit following the manufacturer’s instructions. 
 
Ethanol precipitation of DNA  
The addition of ethanol to nucleic acids depletes their hydration shell and 
exposes the negatively charged phosphate groups in the backbone of the 
DNA. Na+-ions bind to these groups so that a precipitate can form. To 1 
volume of DNA solution 1/10 volume of 3M Na-Acetate (pH 5.2) and 2.5 
volumes of 100% ethanol were added and mixed on a vortex. The DNA was 
precipitated at –20°C for 1 hour, pelleted by centrifugation at 20,000g and 
washed with 1ml of 70% ethanol. The DNA pellet was dried for 5–10 minutes 
at room temperature and resuspended in 10 mM Tris (pH 8.0). 
 
Polymerase chain reaction (PCR)  
The polymerase chain reaction is a method to amplify DNA-sequences of 
interest 129. To produce multiple copies of DNA two specific primers are used 
that are complementary to one of the two strands. Denaturing of the DNA is 
followed by a fall in temperature so that the primers can anneal to their 
complementary sequence on the DNA. Taq-DNA polymerase catalyzes the 
replication of the DNA by adding nucleotides (dNTPs) to the 3’-ends of the 
primer sequences. By repeating these steps several times the DNA-sequence 
of interest is amplified exponentially. 1ng of plasmid DNA or 10 to 200ng of 
genomic DNA were diluted in 1x reaction buffer and used as a template for 
the PCR. After addition of 10pmol forward primer, 10pmol reverse primer, 
10mM dNTPs and 1Unit of Taq-polymerase the PCR was run on a Perkin 
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Elmer 9700 PCR machine. The reaction was started by denaturing the DNA 
for 5-10 minutes at 95°C followed by 35 cycles of denaturing for 1 minute, 
annealing of primers at 55-70°C for 1 to 1.5 minutes and extension of the 
sequence at 72°C for 1 to 3 minutes, followed by a final incubation at 72°C for 
10 minutes. The times, temperatures and number of cycles were chosen 
according to the polymerase used, the melting point of the primers and the 
sequence to be amplified (Sigma). 
 
Site-directed mutagenesis  
A modified PCR protocol was routinely used to mutate one or more 
nucleotides in a given sequence in a plasmid. In brief, primers were designed 
in the region that was supposed to be mutated, in both directions, containing 
the desired changes in the nucleotide sequence. After the PCR the reaction 
mixture was incubated with DpnI restriction enzyme, which digests only 
methylated DNA. A newly synthetized plasmid containing the mutation is not 
methylated and therefore remains intact and can therefore be isolated on a 
agarose gel. The QuikChange Site-Directed Mutagenesis Kit was used 
according to the manufacturer’s instructions (Stratagene). 
 
DNA sequencing 
DNA cycle sequencing is based on the dideoxy method developed by 
Sanger130. In the cycle sequencing reaction all four dideoxynucleotides (A, T, 
G, C) labeled with different dyes were added to an excess of 
deoxynucleotides. When one of the labelled dideoxynucleotides is 
incorporated, the elongation of the chain is terminated because the labelled 
nucleotides lack the 3’-hydroxyl group. The reaction mixture is then applied to 
a ABI Prism gel capillary and separated according to their molecular weight 
(ABI Prism 7700 Sequence Detector). Different wavelengths are used to 
excite each dye and thus to identify the sequence of the DNA. 1µl DNA 
containing 200-500ng plasmid DNA, 1µl primers (10pmol end concentration), 
4µl Ready Mix and 6µl H2O were mixed in a reaction tube. The DNA cycle-
sequencing reaction was carried out using the following program: 96°C 15 
seconds; (96°C 30 seconds, 50°C 30 seconds, 60°C 4 minutes) for 25 cycles; 
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4°C. DNA was precipitated in ethanol and washed with 70% ethanol. The 
DNA pellet was resuspended in 12µl Template Suppression Reagent and 
prior to sequencing incubated on a shaker platform for 5 minutes. For the 
capillary gel run and detection of fluorescent dyes the ABI PRISM 310 Genetic 
analyzer was used. 
 
Northern blotting 
Northern blotting and hybridization is a tool to measure the amount, 
abundance and size of RNAs. RNA was separated according to its size by 
electrophoresis through a formamid denaturing agarose gel. The RNA was 
transferred from the gel to a nylon HyBond N+ membrane (Amersham) by 
upward capillary transfer overnight and immobilized on the membrane. To 
identify RNAs of interest the membrane was incubated with a radioactive 
labeled probe that binds to complementary RNA sequences. Results were 
analyzed by autoradiography.  
 
RNA extraction  
RNA extraction was performed as described by Chomczynski131. A 
monophasic lysis reagent is used to lyse cells. The addition of chloroform to 
the lysate generates an organic phase into which DNA and proteins are 
extracted while the RNA stays in the aqueous supernatant. The RNA is 
precipitated from the supernatant with isopropanol. The RNA is resuspended 
in RNase free water and stored at –80°C. Total RNA from brain tissue and 
eukaryotic cells was extracted using Trizol reagent (Gibco) as described 
previously132, according to the manufacturer’s protocol. Briefly, tissues were 
homogenized in 1ml Trizol; to the homogenate were added 0.2ml chloroform 
and centrifuged for 15 minutes at 12,000g at 4°C. The upper aqueous phase 
was transferred into a fresh tube and incubated with 0.5ml isopropyl alcohol 
for 10 minutes at room temperature. The samples were then centrifuged again 
at 12,000g at 4°C for 10 minutes. The supernatant was removed and pellets 
were mixed with 1ml 75% ethanol and centrifuged at 7,500g for 5 minutes at 
room temperature. Pellets were then air dried and dissolved in 10µl RNase 
free water and stored at -80°C for further detection. 
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Preparation of RNA for electrophoresis  
20µg RNA were resuspended in 32µl sample buffer, heated at 68°C for 10 
minutes, chilled on ice and 8µl 5x sample buffer was added. The gel was pre-
run for 3 minutes at 60V, then run at 6V/cm until the bromphenol blue dye 
band had migrated one-half the length of the gel. The gel was examined on 
an UV transilluminator to visualize the RNA and photographed with a ruler. 
28S RNA corresponds to a mRNA size of 4718 bp, 18S RNA to 1874 bp. 
 
RNA Transfer 
The gel was rinsed in DEPC-treated H2O to wash out formaldehyde and 
soaked twice in 10x SSPE for 15 minutes. The membrane was soaked in 10x 
SSPE for 5 minutes. The separated RNA was blotted by capillary transfer with 
10x SSPE overnight on a Hybond-N+ membrane (Amersham). After the 
transfer the membrane was washed twice in 5x SSPE for 15 miutes. The RNA 
was covalently bound onto the membrane by irradiation (120,000 
microjoules/cm2; Stratagene UV-Crosslinker). Then the membrane was 
incubated in 5% glacial acid for 1 minute stained with methylene blue for 3 
minutes. The membrane was washed with DEPC treated water. 
 
Generation of radioactively labelled DNA probes by random prime labelling 
Random labeling of cDNA was carried out using the random prime labeling 
system rediprime II (Amersham Pharmacia Biotech). The target cDNA was 
used as a template for a random synthesis of DNA fragments in the presence 
of short primers (hexanucleotides) and α32P-radiolabeled dCTP, so that 
newly synthesized DNA harboured the radioactive nucleotide. 10 ng of target 
DNA was denatured in 45 µl TE-buffer at 99°C for 5 minutes. The sample was 
chilled on ice for 5 minutes and added to the reaction tube, containing 
hexanucleotides, dATP, dGTP, dTTP and the Klenow fragment of DNA 
polymerase I. After the addition of 5 µl α32P-dCTP with a specific activity of 
3000 Ci/mmol the solution was incubated at 37°C for 30 minutes. The 
QIAGEN Nucleotide Removal Kit was used to remove nucleotides that were 
not incorporated during the reaction and short oligonucleotides (< 100 bp).  
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Hybridization 
The membrane with the cross-linked RNA was placed in a roller bottle and 
pre-hybridized in 10 ml ExpressHyb (Clontech) containing salmon sperm (10 
µg/ml) for 2 hours at 65°C. The labeld probe was denatured for 5 minutes at 
99°C, chilled on ice for 5 minutes and added to the pre-hybridization solution. 
The hybridization was carried out at 65°C for 20 hours. The hybridization 
solution was discarded and the blot was washed in wash buffer for 10 minutes 
at room temperature and twice for 30 minutes at 65°C. The membrane was 
exposed to a Biomax MR film for 10-60 hours at -80°C. 
 
Quantitative RT-PCR 
Primers specific to human and murine seladin-1, 5’-CCGTCCGAAAACTCAG-
3’; 5’-GCGGTGGTAGTAGTGT-3’ and 5’-CATCGTCCCACAAGTATG-3’; 5’-
CTCTACGTCGTCCGTCA-3’ were designed using the program LC probe 
design software (Roche). Seladin-1 mRNA was quantified in three 
independent cell cultures or mouse brains (n=5 for each group). The 
housekeeping genes phosphoglucokinase (PGK) and porphobilinogen 
deaminase (PBGD) were used as reference genes. These two genes were 
selected based on our unpublished results showing a constant expression of 
these genes in various experimental conditions both in vitro and in vivo. Light 
Cycler quantitative real time PCR (LC-PCR) was performed with a RNA SYBR 
Green kit following the manufacturer’s instructions (Roche Diagnostics). In 
brief, one microliter of 10µM primers and 150ng of total RNA was used for 
each reaction. Reverse transcription was performed at 55°C for 10 minutes. 
Amplification was carried out for 45 cycles, each consisting of 1 second at 
95°C, 10 seconds at 58°C followed by 13 seconds at 72°C. Melting curve 
analysis was carried out by heating the reaction up to 95°C with a 
temperature transition rate of 0.1°C/second followed by a stepwise cooling 
process with a temperature transition rate of 20°C/second.  
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Biochemical methods 
 
Western blotting 
Western blotting is a method to identify a protein of interest in an extract or 
homogenate. Proteins are electrophoretically separated by SDS-polyacryl gel 
electrophoresis (SDS-PAGE) and transferred from the gel to a nitrocellulose 
membrane where they can be detected with specific antibodies.  
 
Measurement of protein concentration 
Protein concentrations of cell or tissue extracts were measured as described 
by Lowry et al.,133 using the BioRad DC Protein Assay Kit. Proteins react with 
an alkaline copper tartrate solution and reduce folin reagent. The reduced folin 
species have a characteristic blue color with an absorption maximum of 750 
nm. 
 
Preparation of cell and brain samples for Western blot analysis 
Cells were homogenated with lysis buffer containing by 20 passages through 
a 16G and a 26G needle, on ice. The homogenization of mouse brains was 
done in a glass homogenizer using a Heidolph electronic homogenizer at 
240rpm. 30-60µg protein of the homogenates were mixed with 3x loading 
buffer and heated to 84°C for 5 minutes. After 2 minutes incubation on ice the 
samples were centrifuged at 20,000g for 3 minutes at room temperature.  
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation of proteins was carried out by SDS-PAGE analysis. Proteins were 
dissociated into their polypeptide subunits using the anionic detergent SDS in 
combination with a reducing agent and heat. SDS binds to hydrobhobic 
regions of the polypeptides so that they become negatively charged and 
migrate to the anode. Because the amount of SDS bound is proportional to 
the molecular weight of the protein subunits, the SDS-polypeptide complex 
migrates in the gel according to the size of the polypeptide. For seperation of 
proteins 10-20% and 10% Tris-Tricine gels (Invitrogen) were used following 
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the manufacturer’s instructions. Gels were usually run at 90V for 2-3 hours at 
room temperature. 
 
Transfer of proteins 
Following SDS-PAGE the resolving gel was equilibrated in transfer buffer for 3 
minutes on a shaker platform. Whatman papers and nitro-cellulose 
membranes were cut to the size of the gel and soaked in transfer buffer. The 
gel and the membrane were sandwiched between soaked pieces of a sponge, 
Whatman paper and perforated plastic plates. Blotting was carried out in a 
blotting tank (BioRad) for 2 hours at 300 mA at 4°C.  
 
Detection of glycosylation pattern of proteins 
Protein homogenates were run on a polyacrylamid gel (PAAG) and 
transferred to a nitrocellulose membrane using the above protocol. For the 
detection of glycosylation pattern the DIG Glycan Differentiation Kit (Roche) 
was used. The assays were performed according to the manufacturer’s 
protocol (Roche). Briefly, different carbohydrates bound to proteins were 
characterized using digoxigenin labelled lectins like GNA, SNA, MAA, PNA 
and DSA. Each of these lectins recognizes a specific carbohydrate. 
Specificities of the lectins:  
GNA (Galanthus nivalis agglutinin): recognizes terminal mannose, α(1–3), α 
(1–6) or α (1–2) linked to mannose; thus it is suitable for identifying “high 
mannose” N-glycan chains glycoproteins.  
SNA (Sambucus nigra agglutinin): recognizes sialic acid linked α (2–6) to 
galactose; thus it is suitable for identifying complex, sialylated N-glycan chains 
in combination with the lectin MAA; correspondingly linked sialic acids in O-
glycan structures are also recognized.  
MAA (Maackia amurensis agglutinin): recognizes sialic acid linked α (2–3) to 
galactose; in combination with SNA (see above) it is suitable for identifying a) 
complex, sialylated carbohydrate chains and b) sialic acid linkage. Lectin MAA 
also identifies α (2–3)-linked sialic acids in O-glycans.  
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PNA (Peanut agglutinin): recognizes the core disaccharide galactose α (1–3) 
N-acetylgalactosamine and is thus suitable for identifying O-glycosidically 
linked carbohydrate chains (with exception of yeast glycoproteins). Should the 
disaccharide be substituted, it is necessary to split off the substitute group 
forst (e.g. sialic acid) with the aid of neuraminidase [neuraminidase from 
Arthrobacter or from Vibrio cholerae].  
DSA (Datura stramonium agglutinin): recognizes Galβ-(1–4)GlcNAc in 
complex and hybrid N-glycans, in O-glycans and GlcNAc in O-glycans. 
 
Enzyme-linked immunosorbent assay (ELISA) 
Total extracts of cells were analyzed by a modified sandwich ELISA that 
detects specifically either Aβ40 or Aβ42 according to the provider’s protocol 
(Takeda, Japan)134. Aβ was captured with a specific anti Aβ antibody 
(BNT77). Aβ species ending in residue 40 or 42 were measured using 
horseradish peroxidase-coupled monoclonal antibodies specific for Aβ40 
(HPR-conjugated BA27) and Aβ42 (HPR-conjugated BC05). 
 
Lactate dehydrogenase assay (LDH) 
To determine the cell viability in different culture conditions an LDH assay was 
used. This assay is based on the reduction of Nicotinamide-Adenine-
dinucleotide (NAD) by the activity of the enzyme Lactate dehydrogenase 
(LDH), resulting in a colored compound which is spectrophotometrically 
analysed. The medium of cultured cells in the desired condition was collected 
and centrifuged. It was then mixed with a half volume of assay mixture and 
incubated for 20 minutes at 37°C in the dark. The reaction was then blocked 
using 1/10 volume 1N HCl. The absorbance was detect at of 490nm. All the 
steps were performed according to the manufacturer’s protocol (Sigma, TOX-
7). 
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Immunocytochemistry 
Cells were washed twice with phosphate buffered saline pH7.4 (PBS) and 
fixed for 5 minutes with 4% paraformaldehyde (PFA) pH7.4 at room 
temperature. After two washes with PBS cells were permeabilized with PBS 
containing 0.1% Triton X-100 for 10 minutes and blocked for 3 hours with 5% 
sheep serum and 1% BSA diluted in PBS at room temperature. Cells were 
then washed twice with 1% BSA and 0.05% Triton X-100 diluted in PBS. The 
primary antibody was diluted in blocking buffer and incubated overnight in a 
wet chamber at 4°C. The cells were then washed twice with 0.05% Tween-20 
in PBS for 5 minutes. The secondary antibody (Amarsham), conjugated with a 
fluorescence marker was diluted in blocking buffer, added to the cells and 
incubated for 2 hours at room temperature in the dark. The cells were then 
washed three times with PBS for 5 minutes and embedded in Moviol. 
 
Immunohistochemistry for brain sections 
Frozen sections were washed twice with PBS and fixed for 30 minutes with 
4% PFA pH7.4 at room temperature. After two washes sections were 
permeabilized with PBS containing 0.1% Triton X-100 for 20 minutes and 
blocked for 5 hours with 5% HS diluted in PBS at room temperature. Sections 
were then washed twice with 5% HS and 0.05% Triton X-100 diluted in PBS. 
The primary antibody was diluted in blocking buffer and incubated with the 
sections overnight in a wet chamber at 4°C. The brain slides were then 
washed twice with 0.05% Tween-20 in PBS for 10 minutes. The secondary 
antibody (Amarsham), conjugated with a fluorescence marker, was diluted in 
blocking buffer, added to the sections and incubated for 2 hours in the dark. 
The sections were then washed three times with PBS for 5 minutes and 
embedded in Moviol. 
 
Terminal deoxynucleotidyl transferase mediated dUTP nick end 
labelling assay (TUNEL)  
TUNEL staining was performed on cells fixed in 4% PFA. Briefly, cells were 
incubated with 0.1% Triton X-100 (Sigma) in PBS at 4 °C for 2 minutes, 
blocked with 3% H2O2 in methanol for 10 minutes, washed in PBS and 
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incubated with 50µl TUNEL mix solution containing terminal deoxynucleotidyl 
transferase and digoxigenin-labelled dUTP (Roche) at 37°C for 90 minutes. 
Cells were then washed with stop/wash buffer and incubated with 50µl 
Converter-POD at 37°C for 30 minutes. The cells were rinsed twice with PBS, 
incubated with 100µl DAB substrate for 10 minutes at room temperature and 
mounted with Moviol.  
 
Annexin-V staining 
During early apoptosis, most cell types translocate the membrane 
phospholipid phosphatidylserine (PS) from the inner face of the plasma 
membrane to the cell surface. Once on the cell surface PS can be detected by 
staining with a fluorescent conjugate of Annexin V, a protein that has a strong 
natural affinity for PS. Annexin V can therefore be used as an early indicator 
of apoptosis135. Annexin-V staining was performed on fresh trypsinized cells in 
suspension. 104-105 cells were incubated in 500µl binding buffer (LabForce) 
containing 5µl Annexin-V Cy3 fluorescence conjugated (LabForce) for 5 
minutes at 4°C in the dark. Apoptotic cells were detected using cytometry as 
described below. 
 
Cytometry  
Seladin-1 overexpression was detected by intracellular staining of the HA-
tagged transgene. Prior to staining cells were fixed in 4% PFA for 10 minutes, 
washed and permeabilized using 0.1% Triton X-100 for 5 minutes at room 
temperature. The cells were incubated with an FITC conjugated anti-HA 
antibody (MBL Int. Co.) for 20 minutes at 4°C in the dark. After washing, cells 
were resuspended in PBS containing 0.2% fetal calf serum (FCS) and 
analyzed in a FC500 cytometer using CXP software. 
 
Analysis of lipids contents 
SH-SY5Y cells or mouse brains were homogenized in PBS containing 9% 
sucrose and protease inhibitors (CLAP: pepstatin, antipain, chymostatin, each 
at a final concentration of 25µg/ml) using a dounce homogenizer and 10 
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passages through a 22 gauge syringe on ice. The samples were centrifuged 
at 700g for 10 minutes at 4°C and the supernatants were considered as total 
extracts. A further centrifugation was performed at 100,000g for 1 hour at 4°C 
to pellet the membrane fraction.  
Lipids were extracted from membrane pellets according to Bligh and 
colleagues136. Extracted lipids (cholesterol and sphingomyelin) were 
subsequently analyzed by thin-layer chromatography (TLC) on silica gel 60 
HPTLC plates using a two-step system (hydrophilic running solvent: 
chloroform/acetone/acetic acid/methanol/water (50:20:10:10:5) (Sigma) and 
hydrophobic solvent: Hexane/ethyl acetate (5:2)) (Sigma). The ganglioside 
GM1 was analyzed by slot-blot using cholera toxin subunit B peroxidase 
linked (Sigma). Quantification was done by densitometry of the scanned TLCs 
or autoradiograms using the NIH-image software. 
To determine the sterol concentration, cells were washed once with ice-cold 
PBS containing 2mg/ml BSA (Sigma) and twice with PBS. The sterols were 
extracted twice from confluent cells grown in a tissue culture dish (diameter 
10cm) or from frontal brain regions expanding from interaural regions 6 to 4 
using 4ml hexan/isopropanol (3:2) containing 1µg epicoprostanol as internal 
control. Gas Chromatography-Mass Spectroscopy analysis was performed as 
described to determine the total levels of the extracted sterols137. In addition, 
cholesterol was measured in total and membrane extracts containing equal 
amount of protein (40µg) using the Ecoline 25 cholesterol kit (Merck). Ecoline 
relies on the enzymatic oxidation by cholesterol oxidase of cholesterol and its 
esters producing H2O2. This is converted into a colored quinonimie in a 
reaction with 4-aminoantipyrine and salicylic alcohol catalyzed by peroxidase. 
The optical density was measured at 500nm. Pure cholesterol (Sigma) diluted 
in 95% ethanol were used as standards. 
 
DRM isolation 
Total SH-SY5Y cell extracts were incubated for 1 hour at 4°C in 1% Triton X-
100, 25mM MES pH7.0, 5mM DTT, 2mM EDTA and CLAP. The extracts were 
mixed with 90% sucrose prepared in MBS buffer to reach a final concentration 
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of 60% and overlaid in an SW40 centrifugation tube (Sorvall) with a step 
gradient of 35 and 5% sucrose in MBS. After centrifugation at 100,000g 
(Sorvall) for 18 hours at 4°C, eleven fractions were collected from the top of 
each tube. Fractions 4-6 were identified as the DRM fraction138 by the 
presence of the detergent resistent microdomain markers flotillin 1 and GM1 
in the control samples.  
 
Plasminogen binding and plasmin activity 
Plasmin enzymatic activity was assayed using the chromogenic substrate S-
2251 (Chromogenix) specific for this protease. 200µg of freshly prepared 
membrane extracts from SH-SY5Y cells were resuspended in Hank’s 
balanced saline solution (HBSS) and 0.1% Ovalbumin (Sigma). They were 
placed in a 96 multiwell plate in the presence of 2mM chromogenic peptide to 
measure endogenous plasmin activity. Absorbance was measured at 37°C 
and 405nm in an ultra microplate reader Elx808iu (BioteK, instruments, INC) 
every 5 minutes for 45minutes. To determine plasminogen binding, 2µM 
human plasminogen was also added to the membrane fractions and plasmin 
activity was measured.  
 
Cell biology methods 
 
Cell culture 
Human neuroblastoma (SH-SY5Y) cells were cultured  in DMEM-F12 
medium, 2 mM L-glutamine, 1 mM sodium pyruvate, 10% fetal calf serum 
(FCS), 5% HS, 50U/ml penicillin and 50µg/ml strepomycin. Cells were 
cultivated at 37°C, 5% CO2 and 95% humidity. Confluent cells were washed 
with PBS, trypsinized with trypsin/EDTA (Invitrogen) and passaged. Cells 
were resuspended in freezing medium and stored in liquid nitrogen. Human 
SH-SY5Y neuroblastoma cells were transfected either with HA tagged 
wildtype or mutant seladin-1 cDNA constructs using LipofectAmine 2000 
(Invitrogen) according to the manufacturer’s protocol, followed by a selection 
with 125µg/ml G418 for 30 days. Pools of selected clones were seeded on 
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collagen type I (Sigma) coated dishes at a density of 0.3-2.0 x 104 cells/cm2, 
depending on the type of experiment (low density culture for 
immunocytochemistry, and high density culture for Western blot analysis).  
 
Tissue preparation 
Mice were perfused transcardially under deep anesthesia (with an overdose of 
Rompun Bayer Veterinaria) using a peristaltic pump connected to two 
reservoirs containing saline and fixative solution. A cut along the sternum was 
made in order to expose the end of the sternum, then, with sharp scissors, a 
cut was made through the skin, diaphragm and laterally on both sides upward 
across the ribs parallel to the lungs; the cannula was then inserted through the 
left ventricle into the ascending aorta. The right auricle was cut with a surgical 
pair of scissors to allow the escape of return circulation. Perfusion was 
performed initially with PBS, pH 7.4 for 10 minutes at room temperature, 
followed by 4% PFA in PBS on ice. Brains were removed and immersion-fixed 
in 4% PFA overnight at 4°C. Immunohistochemistry was performed either on 
thick (12µm) cryostat (Leica) sections or on thin (5µm) paraffin sections 
(Leica). For cryostat sectioning, brains were subsequently incubated in 10%, 
20% and 30% sucrose for cryprotection. For paraffin sections, tissue was 
subsequently dehydrated in an ascending ethanol series followed by xylol 
incubation prior to paraffin embedding. 
 
Primary neuronal cultures 
Primary neuronal cultures were prepared from c57Bl/6 wildtype mice. The 
cortex was dissected and kept in ice-cold Hank's balanced salt solution 
(HBSS; 10 mM HEPES, pH 7.3) (Gibco) and then incubated at 37 °C for 30 
minutes in Ca2+/Mg2+-free HBSS containing 0.25% trypsin (Gibco) and 0.2 
mg/ml deoxyribonuclease (Sigma). The cortical tissues were dissociated to 
single cells by gentle trituration. The cell suspension was mixed with 
Neurobasalmedium  supplemented with B27 (Gibco), 0.5mM glutamine, 50 
U/ml penicillin, and 50µg/ml streptomycin. The cell suspension was 
centrifuged at 310g for 3 minutes and the resulting pellets were resuspended 
in the medium described above and plated onto polyornithin/laminin (Sigma) 
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coated 12-well plates with one coated glass cover slip in each well. The cells 
were cultured in a CO2 incubator (5% (v/v), 37 °C) for 5 days before treatment 
with SFV. 
 
Semliki Forest Virus preparation 
Semliki Firest virus (SFV) is a positive strand RNA virus of the alphavirus 
genus that can infect differentiated neurons. A heterologous gene in the 
‘vector RNA’ replaces the viral structural protein genes that are required for 
encapsidation of viral RNA. Vector RNAs are self replicating and referred to 
as ‘replicons’. Replicons must be cotransfected with a ‘helper RNA’ to be 
packaged into infectious particles. Kits for the production of packaged SFV 
are commercially available (SFV, Life Technologies). In short, seladin-1 cDNA 
was cloned into pSFV2 plasmid using BamHI/XhoI restriction sites. The 
plasmid was transfected into XL-2 Gold bacteria (Invitrogen) and DNA was 
extracted. The purified plasmid was linearized using NruI restriction enzyme 
and purified. The plasmid containing the cDNA for the production of structural 
nsP1-4 Seladin-1(HA)AAA
Structural genes AAA
Replicase complex E1, p62Capsid
nucleocapsid
α-Chymotrypsin
Production of Selmiki Forest Viruses modified to express the human seladin-1  
BHK-21 cells are cotransfected with a nsP1-4 viral replicon containing seladin-1 mRNA and 
a helper RNA expressing the structural genes of the virus. Cells transfected with both RNAs 
produce an inactive virus, which contain the seladin-1 mRNA. The virus is activated after an 
α-Chymotrypsin digestion. 
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genes (helper RNA) was linearized using SpeI. Both linearized plasmids were 
reverse transcribed to RNA as described by Lundstrom and colleagues139 
using the in vitro transcription SuperScript kit (Gibco). To produce the virus, 
baby hamster kidney (BHK-21) cells (kindly provided by Markus Ehrengruber) 
were cultured to 80% confluency and transfected with both RNAs in a ratio of 
1:1 using LipofectAmine (Invirogen). After 2-3 days the medium was collected. 
The virus was activated by adding 500µg/ml α-Chymotrysin (Sigma) to the 
medium containing the packaged replicons, after 30 minutes incubation at 
room temperature the reaction was stopped with 250µg/ml aprotinin (Sigma). 
α-Chymotrysin cleaves the spike precursor protein p62 at a leucine residue, 
resulting in the formation of mature E2 and E3 spike protein, which lead to the 
activation of the virus.140 
 
Alphavirus mediated gene transfer into neurons 
Primary neuronal cultures were prepared as described above. The activated 
SFV was added directly to the medium with an approximate titer of 104 
infectious units. Cells were incubated during 48 hours in a tissue culture 
incubator (5% CO2, 37°C). During this time the virus can activate its replicase 
nsP1-4 seladin-1(HA) AAA
Replicase
complex seladin-1 (HA)
Selmiki Forest Virus infection of postmitotic neurons 
Selmiki Forest Virus infects the neurons via viral E2 and E3 spike proteins. Once the RNA 
has been released into the cytoplasma of the neuron, it can express the exogenous seladin-
1(HA). 
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*P =0.01-0.05, **P=0.001-0.01, ***P=0.0001-0.001. 
machinery and transcribe the cloned gene using the neuronal transcription 
and translation factors. An incubation period of two days was optimized for 
neuronal cultures.  
 
Intracranial stereotaxic injection 
Four month-old c57Bl/6 mice were anesthetized with Ketalar/Rompun, placed 
in a Kopf stereotaxic instrument, and an incision was made along the midline 
to expose the skull. The calvarium was perforated with a dentist borer and 1µl 
of a suspension of cells in MEM was injected into the hippocampus, according 
to Bregma coordinates defined as caudal, lateral and ventral measures (-1.9; -
1.0; -1.9) over a period of 5 minutes using a 10µl Hamilton syringe positioned 
with a stereotaxic instrument. The syringe was slowly withdrawn, and the 
wound was closed with surgical staples. 
http:// www.kopfinstruments.com
ve
nt
ra
l
ca
ud
al
lateral
ve
nt
ra
l
Bregma (0;0;0)
Lambda
injection(-1.9;-1.0;-1.9)
Schematic figure for stereotaxic injections 
Left panel: Kopf stereotaxic apparatus. The mouse is placed and fixed by means of two 
ear bars and a mouth-piece, the exact coordinates for injection can be red on an 
appropriate scale (caudal, lateral and ventral). Right panel: Representation of a mouse 
skull. Once the skull is exposed by incision with a scalpel, the Bregma and Lambda points 
are visible, starting from the Bregma, the appropriate coordinates are calculated (e.g. -
1.9:-1.0:-1.9 for the CA1 region of the hippocampus). 
 
 
Statistical analysis 
Data were collected and statistically analyzed by non-parametric Mann–
Whitney U test using theSPSS program. In all graphs mean ± SE (standard 
deviation of the mean) are shown. P values <0.05 were considered 
statistically significant. Statistical significance is indicated by asterisks:  
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Results 
 
Cloning and mutagenesis of human seladin-1 
To study the effect of seladin-1 overexpression in vitro we subcloned the open 
reading frame (ORF) of the human seladin-1 cDNA in neuroblastoma cells. 
Since seladin-1 is a putative substrate for caspases5 we generated two 
additional constructs with point mutations at the presumed cleavage sites of 
either caspase-3 at AA 122 (D474E) or caspase-6 at AA 182 (D1256E) (Fig 
1). Both point mutations block caspase activity because the amino acid 
aspartate, which is necessary for caspase cleavage, was substituted by 
glutamate. All three constructs were tagged with a haemagglutinin (HA) 
sequence at the 3’-OH end and were cloned into the expression plasmid 
pcDNA3 driven by a CMV promoter. As control construct we cloned EGFP in 
pcDNA3.  
 
Analysis of transgene expression  
Human neuroblastoma (SH-SY5Y) cells were transfected with the wildtype 
seladin-1 cDNA construct (sel) and the constructs mutated at the putative 
caspase-3 (474) and caspase-6 (1256) cleavage sites. As control cultures we 
Figure 1 Cloning, mutations and tagging of human seladin-1 cDNA 
 The human seladin-1 cDNA was tagged with an haemagglutinin sequence at the 3’-OH end 
and subcloned. Point mutations were inserted at the two putative caspase cleavage sites 
(caspase-3, D474E and caspase-6, D1256E). 
Caspase-3 cutting site
-ATT CTG GAA GTG GA A ACC-
Ile Leu Glu Val   Glu Thr
-ATT CTG GAA GTG GAC ACC-
Ile Leu Glu Val Asp   Thr
Caspase-6 cutting site
-CAC GTG GTG CAG GAC ATG -
His    Val     Val    Gln Asp   Met
-CAC GTG GTG CAG GA A ATG -
His    Val     Val    Gln Glu Met
Seladin-1 (474) Seladin-1(1256)
5’ 3’
HA
5’ 3’
474
HA
5’ 3’
1256
HA
Wt Wt
FAD FAD
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transfected the EGFP construct (EGFP) and for mock-transfected c
we transfected the pcDNA3 vector (control). To obtain stable expression we
selected the cultures for five we
ontrol cells 
 
eks with neomycin. The expression of the 
transgene was analysed by Western blotting using a polyclonal anti rat 
antibody against the HA tag. The transgenes were visible at the size of 60kDa 
confirming the expression of the transfected cDNAs (Fig 2a). Control cells did 
not show any transgenic expression. The loading was controlled by a β-actin 
staining. The different intensities of the HA-bands in Figure 2 implied a certain 
difference in the percentage of transfected cells between the three cultures. 
Cytometry and immunohistochemistry confirmed these differences and 
revealed that in the seladin-1 overexpressing culture 30% of the cells stably 
expressed the  transgene. In the two mutant cell lines we found 22% of the 
cells expressing the 474 and 16% expressing the 1256 construct (Fig 2b).  
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Figure 2 Analysis of SH-SY5Y cells expressing different seladin-1 constructs 
(a) Western analysis of seladin-1 overexpressing cells (lane 2), 474 cells (lane 3) and 1256 
cells (lane 4) using an anti HA antibody show the e  
 
 
 
 
 
expressed the transgene. 
xpression of the transgenes. No specific
band corresponding to HA could be detected in control cells (lane 1). β-actin staining showed
that similar amounts were loaded on the gel. (b) Cytometric analysis of seladin-1HA
expression. In seladin-1 overexpressing cultures 30% of the cells are stably expressing the
transgene. In 474 and 1256 cultures 22% and 16% of the cells are expressing the mutated
transgenes, respectively (c). Immunocytochemistry. HA-staining and phase images of SH-
SY5Y cells transfected with human seladin-1. The overlay shows that ± 30% of the cells stably
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ell 
iability, we measured lactate dehydrogenase (LDH) in the supernatant of the 
cells. LDH is a mitochondrial protein which is released when the cell 
membrane is damaged, and the assay is based on the reduction of NAD by 
seladin-
Induction of apoptosis and analysis of surviving cells  
To analyze the anti-apoptotic function of seladin-1 and the possible role of 
caspases in this process we subjected seladin-1 overexpressing wildtype 
cells, mutated cells lines 474 and 1256 and mock transfected control cells to 
apoptotic stimuli. Since there are many insults which can trigger a variety of 
mechanisms leading to the induction of programmed cell death we treated the 
cells with four different substances. H2O2 results in general oxidative stress by 
the production of oxygen radicals whereas tunicamycin selectively induces ER 
stress. Etoposides block the function of the topoisomerase II during DNA 
replication and therefore induces apoptosis during cell division. The Aβ 
peptide is thought to be the primary toxic agent responsible for nerve cell 
death in AD. The mechanisms involved in Aβ are not known completely and 
include protein oxidation and lipid peroxidation.141 For assessment of c
v
the action of LDH. For the detection of apoptotic cells we used the terminal 
deoxynucleotidyl transferase, which catalyses the addition of labeled 
nucleotides to free 3’-OH DNA ends in a template independent manner 
(TUNEL-reaction). For cytometric analysis of apoptotic cells we labelled 
membrane phosphatidylserine using Annexin-V. During early apoptosis, most 
cell types translocate the membrane phospholipid phosphatidylserine (PS) 
from the inner face of the plasma membrane to the cell surface. Once on the 
cell surface, it can be detected by staining with a fluorescent conjugate of 
Annexin V, a protein that has a strong natural affinity for PS135. Double 
staininig using FITC labeled Annexin-V and TRITC marked anti HA antibody 
was performed for quantification of the survival rate of apoptotic cells 
expressing seladin-1 or its mutated forms. To evaluate the protective function 
of our transgene product, we assessed cell viability after treatment of 
1 overexpressing and control cells with 100µM H2O2 for 30 minutes and 2 
hours. LDH measurements revealed that cell viability in seladin-1 
overexpressing cells was only slightly affected by the H2O2 treatment, 
whereas after 30 min viability in control cultures was reduced to 47% and this 
 
  50 
R
E
S
U
L
T
S
effect increased after 2 hour of treatment (23%) when compared to non 
treated controls (Fig 3a).  
Given that wildtype seladin-1 overexpression is protective against induced cell 
death we next analyzed the cultures containing the caspase mutations 474 
and 1256 to evaluate the role of caspases in this process. After 5 hours of 
H2O2 treatment we performed TUNEL staining to assess cells undergoing 
apoptosis. Seladin-1 overexpressing cells were significantly more resistant  to 
the toxic insult than control cells (mortality rate 53%±9.3% and 85%±3.3%, 
respectively, mean±SE, P<0.05), confirming the anti-apoptotic function of 
seladin-1. The surviving rate of 474 cells was also significantly increased 
(mortality rate 57%±4.1%, mean±SE, P<0.05) whereas the 1256 cells did not 
significantly differ compared to control cells (Fig 3b). Similar results were 
obtained when comparing TUNEL positive cells of sel, 474, 1256 and control 
cultures after treatment with etoposides, an inhibitor of topoisomerase 2. 
Wildtype seladin-1 overexpressing cells were significantly less affected than 
control cells (mortality rate 23%±10.4%, mean±SE, P<0.05). A trend towards 
less apoptotic cells but no significant reduction was evident in 474 cultures. In 
1256 cultures the number of apoptotic cells was similar to control cultures (Fig 
3c). We next treated the cells with oligomeric and fibrillar forms of Aβ40 
peptide for 24 hours and did cytometric analysis of the Annexin V staining for 
assessment of apoptotic cells. After treatment with oligomeric and fibrillar Aβ40 
peptide the percentage of apoptotic cells in the wildtype seladin-1 
overexpressing and 474 cultures was smaller compared to 1256 and control 
cultures, but only a border-line significance was found. After treatment with 
oligomeric Aβ40 the overall number of apoptotic cells in all groups was greater 
when compared to the treatment with fibrillar Aβ40 (Fig 3d,e). 
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Seladin
igure 3 Anti-apoptotic role of seladin-1 
-1 overexpressing cultures survive significantly better after 30 minutes and 2 hours 
H2O2 treatment when compared to control cultures (a). After 5 hours of H2O2 treatment 
overexpressing seladin-1 and 474 cells reveal a significant increase in survival when 
compared to 1256 and control cultures (b). 18 hours of etoposides treatment shows no 
differences between the four groups (c). Cultures incubated with oligo and fibrillar Aβ40 do not 
reveal significant differences in cell survival (d,e).  
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Expression levels of seladin-1 after induction of apoptosis 
To investigate the expression of the endogenous seladin-1 during apoptosis 
we treated SH-SY5Y cells with 200µM H2O2 and harvested the cells during 8 
hours at different time points. An increase of the endogenous seladin-1 
protein level was already detectable 1 hour after the insult and the levels 
remained elevated during the entire treatment. (Fig 4).  
 
Intracranial injection of SH-SY5Y cells overexpressing seladin-1HA and EGFP  
Given the anti-apoptotic function of seladin-1 in a cell culture system we next 
analyzed whether the overexpression of seladin-1 in SH-SY5Y cells affects 
their survival in vivo. We injected wildtype seladin-1 overexpressing and 
control cells expressing EGFP intracranially into c57bl/6 mice. The cells were 
plated the day before the injection at a confluency of 40% in normal culture 
medium (Fig 5 left panels). Cells were trypsinized and resuspended in MEM 
without FCS, HS or antibiotics, and diluted to 3,500 cells per microliter. The 
mice were anesthetized and injected with 3,500 cells with a rate of 0.2µl per 
minute. Two and four weeks after the injections the mice were perfused with 
PBS followed by 4% PFA. 15µm cryosections were cut and analyzed. 
No differences were detected in proliferation and in the distribution of the 
cells. Both cultures proliferated to the same extend and after two weeks 
e ability to grow as tumors (Fig 5a). The 
overexpression did not affect their survival rate in vivo. Moreover, when a 
ixture of seladin-1 and EGFP overexpressing cells were injected into the 
rain, no difference was observed in their survival rate. (Fig 5b). Furthermore 
0 1 6 8 0
sel
β actin
Figure 4 Seladin-1 protein levels during 
apoptosis induced with H2O2 
SH-SY5Y cells show increased seladin-1 
protein levels after an apoptotic insult. 
Already 1 hour after H2O2 treatment 
endogenous seladin-1 levels are elevated and 
remain increased during 8 hours of treatment.
seladin-1 and EGFP cells revealed th
cells were not removed by the mouse immune system, suggesting that these 
cells are able to exhauste the mouse defence system independently of the 
expressed transgene. Taken together, these data suggest that seladin-1 
m
b
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to ensure that this fact is only valid for growing tumor cells, we 
predifferentiated the seladin-1 and EGFP cells, culturing them in medium 
containing 15nM retinoic acid during 5 day and used them for injections. In 
both groups no cells were detected in the injected region one week after the 
injections. These data show that predifferentiated cells do not develop into 
tumors and that overexpression of seladin-1 cannot rescue predifferentiated 
cells when injected into a mouse brain with a functional immune system. 
 
 
I II III IV
SH-SY5Y selHA
2 weeks after inject oni 4 weeks after injectionprobe of injected sample
I
II III
a
SH-SY5Y EGFP
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IV
V V
b
Figure 5 Stereotactic injections of SH-SY5Y cells into c57BL/6 mice 
(a) SH-SY5Y cells over expressing seladin-1 and EGFP were injected intracranially into c57Bl/6. 
The left panel (I and IV) shows a representative culture of injected cells. The middle and right 
panels show the injected brains with the grown tumor 2 (II and V) and 4 (III and VI) weeks after 
injection, respectively. Upper pictures show seladin-1 and lower pictures show EGFP implanted 
brains. (b) Brain sections from injected mice with a mix of SH-SY5Y cells overexpressing seladin-
1(HA) and EGFP. Pictures represent hippocampus section containing the mix of injected cells 
stained with HA antibody (red) for seladin-1(HA) (I) and EGFP antibody (green) (II); the same 
section in overlay (III) and overlay in contrast phase light is shown in (IV). No differences are 
visible in growth and distribution of seladin-1 and EGFP overepresssing cells. 
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Semliki Forest Virus (SFV) transduction of primary neuronal cultures 
We designed semliki forest virus containing wildtype seladin-1, 474 and 1256 
RNA to overexpress seladin-1 in primary neuronal culture. The obtained 
maximal virus titer in our system was 7.107 infectious units per µl (stock 
concentration). Primary neuronal cultures were incubated with different virus 
concentrations. Neurons infected with virus titers smaller than 7.104 survived 
the treatment but revealed an infection efficiency of only 1-4% (Fig 6). 
Neuronal cultures infected with greater virus titers did not survive the 
treatment independently of the transgene. Due to the low transfection 
efficiency, this gene transfer system would only allow immunocytochemical 
analysis of the small amount of transfected cells. For any biochemical analysis 
this system was not suitable within this protocol.  
 
ouse brains.  
a b
Fig
Two  
with  
the
ure 6 Primary neuronal cultures infected with selmiki forest virus (SFV) 
 representative pictures of primary neuronal culture from wildtype c57Bl/6 mice infected
 SFV containing seladin-1 (a) and 474 (b), respectively (red). The infection efficiency of
 SFV was about 1 to 4%. Neurons were stained using anti MAP2 antibody (green). 
To ensure that the obtained results were not only an in vitro effect, we 
stereotactically injected the virus containing EGFP into mouse brains. We 
found a minor amount of EGFP expressing cells around the injection tract but 
no transfected cells could be detected in other regions of the hippocampus. 
These results confirmed the in vitro data and led us to the conclusion that the 
infection efficiency in our system was too low to obtain enough transfected 
cells to analyse the effect of seladin-1 overexpression in primary neurons or in 
m
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.003, n=3, Fig 8b,) and 1.7 fold in total cellular cholesterol 
=0.001, n=3, Fig 8c) were found in seladin-1 overexpressing cells when 
Modifications of seladin-1 
To determine whether seladin-1 is post-translationally modified, the 
gycosylation- patterns of seladin-1 were analyzed in seladin-1 overexpressing 
SH-SY5Y cells. Figure 7 shows a 70kDa prominent band appearing in all blots 
stained with the different agglutinins; GNA, SNA, MAA, PNA, DSA. The 
positive control, a Western blot probed with an anti-HA antibody, shows the 
real size of seladin-1 and revealed that the stained band on the agglutinin blot 
is not seladin-1. This strongly suggested that seladin-1 is not glycosylated in 
our conditions.  
PNA   DSA    GNA    SNA    MAA    Seladin-1
148
98
50
64
Figure 7 Glycosylation analysis of seladin-1 overexpressing cells  
Membranes were stained using different agglutinins to detect sugars bound to seladin-1. 
Lane 1 to 5: a prominent band at about 70kDa appears in all tested lectine membrane 
din-1 as stripes. Last lane: Western blot probed with anti-HA antibody to detect sela
positive control. Seladin-1 is significantly smaller than the detected 70kDa band, 
suggesting that seladin-1 is not glycosylated. 
 
Seladin-1 regulates the levels of total and membrane cholesterol in cultured 
human neuroblastoma cells 
To determine to which extent the levels of neuronal cholesterol depend on 
seladin-1 we first analyzed the effects of seladin-1 (sel) overexpression in 
human neuroblastoma SH-SY5Y cells. Quantitative Real-Time PCR of 
seladin-1 mRNA revealed a significant increase (684±121% mean ±SE, 
P=0.0001, n=3) in the seladin-1 overexpressing cultures when compared to 
control cultures (Fig 8a). Significant increases of 1.9 fold in membrane 
cholesterol (P=0
(P
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compared to the control cultures. Desmosterol 
rexpression and therefore reconfirming the bioactivity of the 
transgene. The ratio of the catabolic product 24OH-cholesterol to cholesterol 
 
levels were dramatically 
reduced in cells overexpressing seladin-1 (43±5.2% mean ±SE, P=0.001, 
n=3, Fig 8d) while 24-OH-cholesterol amounts were increased (172±2.3% 
mean ±SE, P=0.00001) when compared to control cultures demonstrating a 
normal catabolism of cholesterol in both conditions. The ratio of desmosterol 
to cholesterol was 2.8 fold (p=0.001, n=4) lower in the seladin-1 
overexpressing cultures (Fig 8e) indicating a dramatic decrease of 
desmostero,l in addition to a drastic increase in cholesterol under conditions 
of seladin-1 ove
did not differ in both cell lines (Fig 8g) demonstrating a normal catabolism of 
cholesterol in both conditions. 
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igure 8 The levels of total and membrane cholesterol depend on seladin-1 
xpression in vitro  
eladin-1 overexpressing SH-SY5Y cultures exhibited significantly higher seladin-1 mRNA 
vels when compared to control cultures (a). Amount of cholesterol expressed in pmol/µg 
rotein in membrane (b) and cellular (c) extracts of control and seladin-1 overexpressing 
H-SY5Y neuroblastoma cells. Amount of desmosterol (d) and 24OH-cholesterol (f) as well 
as ratios of desmosterol (e) and 24OH-cholesterol to cholesterol (g) in control and seladin-1 
verexpressing SH-SY5Y cells. Values were expressed in percentage change to the 
corresponding values in control cells that were considered as 100%. Data in all graphs are 
ean values and standard error from three independent cell cultures. 
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GM1 with high affinity 142) revealed that seladin-1 overexpression leads to the
recruitment of more cholesterol (56±6%, Fig 10a,b), SPM (68.7±11%, Fig
10c,d) and GM1 (67.4±5.5%, Fig 10e,f) in detergent-insoluble fractions 6-4
compared to control cells (42±5% cholesterol, 48.3±12.3% SPM and 57±4%
GM1, P<0.05).  
Seladin-1 contributes to the specific recruitment of DRM proteins and lipids 
into DRMs 
Given the above results and that cholesterol is a main component of DRMs 
we next hypothesized that changes in seladin-1 expression would affect the 
protein and lipid composition of these membrane domains. To test this, total 
extracts of control and seladin-1 overexpressing SH-SY5Y cells were
incubated with 1% Triton X-100 at 4°C and centrifuged on a sucrose gradient. 
Measurement of the amount of total protein in the different gradient fractions 
revealed a significant increase in the light fractions 6-4, which correspond to 
detergent resistant membranes, in the seladin-1 overexpressing cells
compared to control cells (31.6±3.5% and 22.2±3.5% mean ±SE, respectively, 
P=0.01, Fig 9a). To determine whether this increment in protein content was 
the consequence of general or DRM specific protein recruitment the flotation 
profiles of the DRM markers flotillin 1 (Fig 9b) and the GPI-anchored cellular 
prion protein (PrPc) (Fig 9d) and of the non-DRM marker transferrin receptor 
(TfR) were analyzed (Fig 9f). In agreement with a specific recruitment, flotilin1 
and PrPc were enriched in fractions 6-4 of seladin-1 overexpressing cell 
gradients than in control cells while TfR remained in the detergent soluble 
heavy fractions (8-10) in both conditions (Fig 9b,d,f). Quantitative analysis 
showed that while 4.8±2% of total flotillin 1 and 10.4±3% of total PrPc float to 
DRMs in control cells these percentages increase to 18.7±4.6% and 30.5±5% 
(mean ±SE), respectively, in seladin-1 overexpressing cells (P=0.004 and 
P=0.001, Fig 9c,e). To establish whether changes in protein content in DRMs 
were paralleled by changes in lipid composition, the levels of cholesterol,
sphingomyelin (SPM) and the ganglioside GM1, were analyzed in the different 
gradient fractions (Fig 10). Thin Layer chromatography (TLC) (to detect 
cholesterol and SPM) and slot-blot using cholera toxin subunit B (that binds to 
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Figure 9 Seladin-1 regulates the specific recruitment of DRM proteins to DRM 
microdomains 
Total cell extracts contain g 100µg of protein from control and seladin-1 overexpressing 
SH-SY5Y cells were centrifuged in a sucrose gradient. Fractions containing equal volume 
were collected and numbered from the lightest to the heaviest (2 to 10). The amount of 
protein in each gradient fraction is expressed as percentage of the total protein along the 
gradient (a). Representative Western blots of the gradient fractions using antibodies 
against the DRM proteins flotillin 1 (b) and PrP
in
ribution of flotillin 1, PrP  and TfR in each fraction as percentage of 
f flotillin 1, PrPc and TfR, respectively, along the entire gradient (c,e,g). 
control: mock transfected SH-SY5Y cells; seladin-1: overexpressing SH-SY5Y cells. The 
graphs show the average and standard error from three independent SH-SY5Y cultures. 
Asterisks show statistical significance of the differences found in combined fractions 6-4 
that correspond to DRMs. 
c (c), and the non-DRM protein TfR (d). The 
graphs show the dist c
the total amount o
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Altogether these results indicate that seladin-1 is required for the specific
cruitment of DRM protein and lipids into detergent insoluble membrane
omains. 
H-SY5Y cells, seladin-1: overexpressing SH-SY5Y cells. The graphs represent the mean
nd standard errors of three independent SH-SY5Y cultures.Asterisks show statistical 
ignificance of the s differences found in combined fractions 6-4 that correspond to DRMs. 
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Figure 10 Seladin-1 expression affects the amount of lipids in DRMs 
Total extracts containing 100µg of protein from control and seladin-1 overexpressing SH-
SY5Y cells were prepared as described for Figure 15. Where indicated fractions 2-3 and 9-10 
were pooled and analyzed together. The distribution of cholesterol (a) and SPM (c) was 
examined by TLC while slot blot and cholera toxin B linked to peroxidase were used to detect 
GM1 (e). Left panels show representative examples of the gradients. The graphs show the 
amount of cholesterol (b), SPM (d) and GM1 (f) in each fraction as the percentage of total 
cholesterol, SPM and GM1, respectively, along the entire gradient. Control: mock transfected 
S
a
 
  61 
R
E
S
U
L
T
S
PrPc-staining ba
si
ze
 o
f c
lu
st
er
s 
(a
.u
.)
si
ze
 o
f c
lu
st
er
s 
(a
.u
.)
**
TfR-staining
sel
control
c d
sel
control
0
0.2
0.4
0.6
0.8
1
control
sel
0
0.2
0.4
0.6
0.8
1
control
sel
si
ze
 o
f c
lu
st
er
s 
(a
.u
.)
si
ze
 o
f c
lu
st
er
s 
(a
.u
.)
 
Figure 11 increased DRM  size in seladin-1 overexpressing cells 
Seladin-1 overexpression increases DRM size at the cell surface as determined by the antibody 
co-patching method. Living control SH-SY5Y neuroblastoma cells or overexpressing seladin-1 
were incubated with antibodies against the DRM protein PrPc (a) or ag
rotein TfR (c). Images show the immunofluorescence and phase contra
ainst the non-DRM 
p st of representative 
e  
b  
d
old 
 DRM-enriched protein PrPc and the non-DRM protein TfR. Control 
nd seladin-1 overexpressing SH-SY5Y cells were incubated with the above 
ntibodies and the size of PrPc and TfR clusters were determined by 
microscopy (Fig 11a,c). This study revealed a significant increase (p<0.05) in 
xamples in each condition. The graphs indicate the size of clusters observed for PrPc or TfR
y immunofluorescence in arbitrary units (b,d). The data represent mean values and standard
eviation from the analysis of 20 cells in each of three independent cultures per condition. 
 
To determine the significance of the biochemical data obtained using c
detergent extraction in the context of intact, non detergent extracted cells, co- 
patching experiments143 were performed in living cells using antibodies 
against the
a
a
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the size of PrPc co-patches on the surface of seladin-1 overexpressing cells 
(0.7±0.06 arbitrary units/cluster) in comparison to control cells 
(0.3±0.1arbitrary units/cluster, Fig 11b). In contrast, the size of the non-DRM 
protein TfR clusters were not significantly altered by seladin-1 overexpression 
(Fig 11d). Quantitative analysis revealed that their average size was 
0.29±0.05 and 0.28±0.05 arbitrary units/cluster in seladin-1 overexpressing 
and control cells, respectively. Based on these results, we conclude that 
seladin-1 specifically enhances DRM formation at the surface of living cells.  
Seladin-1 regulates DRM dependent plasminogen binding and activation 
gure 12 The DRM-dependent plasminogen binding and plasmin activation rely on selad
vels 
asmin activity (expressed in arbitrary units) was measured at the indicated times in membran
olated from control and se din-1 overexpressing SH-SY5Y cells (a). To monitor plasminog
nding exogenous plasminogen was added to the cellular membranes (b). Membrane extracts (c,e
ndogenous levels of cellular and membrane bound plasminogen were analyzed by Western
ot (d,f) from control and seladin-1 overexpressing SH-SY5Y. Control: mock transfected SH-SY
s; seladin-1: overexpressing SH-SY5Y cells. Data in all the graphs correspond to mean value and
andard error from three independent SH-SY5Y cultures. 
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primary
plasminogen binding in conditions of seladin-1 overexpression. Endogenous 
plasmin activity was measured using a specific chromogenic substrate in 
membranes derived from control and seladin-1 overexpressing SH-SY5Y 
cells. Seladin-1 overexpressing cells exhibited a clear increase in plasmin 
activity (Fig 12a). To analyze plasminogen binding exogenous plasminogen 
was added to isolated membranes and plasmin activity was measured as 
above. Plasmin activity upon addition of exogenous plasminogen was higher 
in seladin-1 overexpressing cells than in control cells, indicating an increased 
ability of seladin-1 overexpressing cell-derived membranes to bind 
plasminogen (Fig 12b). This was further confirmed in endogenous conditions 
by Western blot of SH-SY5Y cell extracts. We observed significant differences 
in the amount of plasminogen bound to the membrane (247±14.7% mean 
±SE, P=0.004, Fig 12e) while there were no changes in the endogenous 
levels of cellular plasminogen in control compared to seladin-1 overexpressing 
cells (Fig 12f).  
 
Seladin-1 overexpression reduces APP β-cleavage in cultured human 
ugh much attention has been given to the effects that a reduction of 
ct BACE1-APP membrane 
segregation and their functional interaction. The flotation profile of BACE1 and 
Given the influence of seladin-1 in DRM composition we reasoned that 
changes in its expression would affect DRM-dependent functions. Because 
plasminogen binding to the membrane leads to the activation of the Aβ 
degrading enzyme plasmin in a DRM-dependent manner144, we decided to 
analyze the plasminogen content and plasmin activity in our experimental 
setup.  
DRMs seggregate a major pool of the APP-β-secretase BACE1 from its non-
DRM substrate APP, restricting APP-β-cleavage and Aβ production in cultured 
 neurons145. in a first step, we therefore analyzed plasmin activity and 
neuroblastoma cells 
Altho
membrane cholesterol has on APP processing, the consequences of higher 
cholesterol levels on APP processing are not known. Hence, we utilized 
control and seladin-1 overexpressing SH-SY5Y cells to determine how the 
induced cholesterol increase would affe
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APP after Triton X-100 extraction at 4°C showed that while APP always 
remained in the heavy fractions more BACE1 was recruited in the light 
fractions (especially the DRM fraction 5) upon seladin-1 overexpression (Fig 
13a,c).Quantitative analysis of the Western blots revealed that while 
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57.4±8.9% of BACE1 is in the APP containing fractions 10-9 in the control 
cells, the percentage diminishes to 35.6±4.3% in seladin-1 overexpressing 
cells (P=0.04, Fig 13b). Consistent with the enhanced membrane segregation 
of BACE1 from APP the generation of APP β-C-terminal fragment was 
significantly reduced (34%, P=0.04) in seladin-1 overexpressing cells (Fig 
13f). Altogether these data demonstrate for the first time that high cholesterol 
levels decrease APP β-cleavage and that this is modulated by seladin-1. 
 
Aβ40 and Aβ42 ELISA 
To confirm the results achieved by Western blot analysis we performed a 
ELISA using antibodies, that specifically recognize Aβ40 and Aβ42. In seladin-1 
overexpressing cells the generation of both Aβ40 and Aβ42 were reduced to 
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Figure 14 Quantification of Aβ40 and Aβ42 in control and seladin-1 overexpressing 
cells 
In seladin-1 overexpressing SH-SY5Y cultures Aβ40 (a) and Aβ42 (b) was significantly 
decreased when compared to control cultures, whereas the ratio of Aβ40 to Aβ42 levels 
did not reveal significant differences between the two groups (c).  
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Functional mutagenesis of seladin-1 cDNA 
o determine the functionality of seladin-1 in the biosynthesis of cholesterol 
and to investigate possible partners involved in its activat
partner(s) of seladin-1, it would be possible to induce a dominant negative 
e 
78.5±4.8 and 71.48±6.7%, respectively (Fig. 14a,b, P=0.001 and 0.003, 
respectively), whereas the ratio of Aβ40 to Aβ42 revealed no significant 
difference (Fig. 14c). These data emphasize the crucial role of seladin-1 
protein in regulating Aβ generation and reconfirm a BACE-dependent 
mechanism for this effect. 
 
T
ion and function, we 
mutated seladin-1 according to the published mutations found in 
desmosterolosis patients 4. These mutations diminish the efficiency of seladin-
1 to reduce sterols at the ∆24 position. If there is one or more essential binding 
effect by overexpressing a non-functional enzyme interacting with thes
partners and therefore inhibiting the binding of the functional protein and the 
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Figure 15 Amount of different sterols in control and mutant seladin-1 (N294T
N294T/K306N) transfected cells 
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A c  
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S  
d ntrol. No differences 
in total amount of the degradation product 24OH-cholesterol were observed. 
mount of cholesterol (a) desmosterol (b) and 24OH-cholesterol ( ) in control, seladin-1
ontaining either single N294T or double N294T/K306N overexpressing SH-SY5Y cells.
ignificant differences in the two overexpressing cell (N294T, N294T/K306N) lines were
etected in cholesterol and desmosterol levels when compared to co
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n a lysin replacing an asparagin at position 306. In 
and the double mutation led to an 
inhibition of enzyme activity of about 80%, whereas the remaining 20% 
enzyme activity enabled the cells
suggest that the partial activity of the transgenes in addition to the 
s  
h  
±  
conversion of the precursor desmosterol. Seladin-1 was cloned into an 
expression vector and mutated using the Qiagen Kit. One construct contained 
a single point mutation leading to a threonin replacing an asparagin at position 
294. The second construct contained the asparagin at position 294 and a 
second mutation resulting i
desmosterolosis patients, the single 
 to reduce desmosterol to cholesterol4. 
Seladin-1 overexpressing SH-SY5Y cells and SH-SY5Y cells overexpressing 
the single and the double mutation constructs were analysed using gas 
chromatography-mass spectrometry. The sterol composition in these cells 
revealed a change in the cholesterol and desmosterol levels when compared 
to control cells. SH-SY5Y cells overexpressing the single (N294T) or the 
double (N294T/K306N) mutation showed a significant decrease in 
desmosterol levels (Fig 15a) and in parallel a significant increase in 
cholesterol amount (Fig 15b) when compared to control cells. These results 
endogenous levels of seladin-1 - which is obviously lacking in desmosterolosis 
patients - are sufficient to reduce desmosterol to cholesterol. Moreover, the 
levels of the degradation product 24OH-cholesterol (Fig 15c) did not change 
in any of the groups. This suggests that seladin-1 does not need a binding 
partner to be activated.  
 
Seladin-1 regulates membrane and cellular cholesterol levels in 
mouse brains  
To determine to which extent the levels of brain cholesterol depend on 
seladin-1 we analyzed the effects of genetic seladin-1 depletion on steady-
state cholesterol levels in vivo. The analysis of seladin-1 mRNA levels in the 
brain of wildtype mice, heterozygous mice with depletion of one 
(heterozygous) or knock-out mice with depletion of both (homozygous) 
94eladin-1 alleles  revealed a gene-dose dependent reduction in the
eterozygous mice compared to their wildtype littermates (43.8±3.3%, mean
SE, P=0.009). There was no seladin-1 mRNA expression detectable in the
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homozygous mice (Fig 16a). The brains of seladin-1 heterozygous mice 
exhibited an average reduction of 29% in the membrane (Fig. 16b, P=0.02) 
and 15% in total cellular cholesterol (Fig 16c, P=0.042) compared to wildtype 
brains. Furthermore, cholesterol amount was undetectable in the homozygous 
mouse brains (Fig 16b,c). To characterize the effect of seladin-1 expression 
on cholesterol metabolism we analyzed the effects of seladin-1 depletion on 
the levels of the cholesterol precursor desmosterol and of the major 
degradation product of cholesterol in the brain, 24OH-cholesterol. 
Desmosterol was 5.7- (P=0.012) and 50-fold (P=0.00006) increased in 
heterozygous and homozygous mouse brains, respectively (Fig 16d), 
indicating that desmosterol accumulates upon seladin-1 deficiency. Moreover, 
decreased seladin-1 expression led to a significant reduction in the catabolic 
product 24OH-cholesterol in heterozygous (24.6±4.3%, mean ±SE, P=0.017) 
and knock-out mice (97.6±0.47%, mean ±SE, P=0.0004, Fig 16e) compared 
to control brains. Altogether, these results confirm the observations from the in 
vitro studies with seladin-1 overexpressing SH-SY5Y cells overexpressing 
seladin-1 showing for the first time the key role of seladin-1 in the regulation of 
brain cholesterol metabolism and homeostasis in vivo. 
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Seladin-1 regulates Aβ generation in vivo  
To determine whether the alterations in membrane cholesterol (shown in 
Figure 15) affect the levels of Aβ, we peformed an ELISA to measure Aβ 
peptides in brain homogenates. Because the endogenous mouse Aβ levels 
are extremely low in young wildtype mice as previously reported146, we 
analyzed aged-matched wildtype and seladin-1 heterozygous mice 
overexpressing the SwAPP mutations147 (SwAPP/seladin-1). Both Aβ40 
(270±31%, mean ±SE, P=0.024, Fig 17a) and Aβ42 (159±0.3%, mean ±SE, 
P=0.015, Fig 17b) levels were significantly higher in SwAPP mice with a 
seladin-1 deficiency when compared to SwAPP littermates, whereas the ratio 
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Figure 17 Levels of Aβ40 and Aβ42 in SwAPP/sel mouse brains 
Quantification of Aβ40 and Aβ42 in brains of seladin-1 wildtype and heterozygous mice 
with the simultaneous overexpression of SwAPP confirmed that seladin-1 deficiency 
leads to higher Aβ steady-state levels. Brain Aβ40 levels showed a significant increase 
in heterozygous (SwAPP/+/- sel) mouse brains compared to seladin-1 wildtype 
littermates expressing solely the SwAPP transgene (SwAPP/+/+ sel) (a). Levels of 
soluble Aβ42 were  also significantly increased in heterozygous (SwAPP/+/- sel) 
mouse brains (b). The ratio of Aβ40 to Aβ42 levels revealed no significant differences 
between the two genotypes (c). 
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of Aβ40 to Aβ42 did not significantly d
 
 
er 
iffer between the two groups (136±31%, 
mean ±SE, Fig 17c). These data suggest that seladin-1 deficiency favored the 
β–cleavage of APP and led to a pronounced increase of Aβ generation in vivo. 
These data show unequivocally that seladin-1 deficiency leads to an 
increased production and accumulation of Aβ in the brain.  
 
Generation of seladin-1 overexpressing mouse line 
The aim of the project was to generate an in vivo model which will confirm the 
neuroprotective role of seladin-1 results demonstrated in vitro. This model 
should allow to reproduce the data showing the role of seladin-1 in cholesterol 
biosynthesis and in DRM organization and function. 
To generate seladin-1 overexpressing mice, the cDNA of human seladin-1
was cloned into the BamHI/XhoI site of the plasmid pEX-12. Expression of the 
transgene was under the control of the neuronal mThy1.2-promoter. Before 
injection into the pronucleus of oocytes the construct was sequenced, 
linearized and purified. Mice were tested for the presence of the transgene by
PCR of mouse tail genomic DNA. For the PCR reaction the sense prim
annealing to the mThy1.2 promoter (O-340(mThy1) 
ATCATGTGCTCCGTGGATC) and  the reverse primer annealing to the 5’ end 
of seladin-1 (0-339-selR GCCGCTGGGACTCGTGGGTGAACTT) were used. 
The PCR product was analysed on a 0.7% agarose gel and the predicted 
band for a positive result was 900bp. The first generation of mice (F1) tested 
for the human seladin-1 cDNA showed that the trangene was transmitted to 
the progeny  (Fig 18). In order to detect the next step in the production of the 
trangene we performed a Northern blot analysis of total RNA isolated from 
PCR positve seladin-1 transgenic mice and their wildtype littermates at the 
age of 5 weeks. 
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mRNA of the transgene. 
mice were positive in the PCR reaction (Fig 19b). We also performed an 
immunohistological staining using a specific anti-seladin-1 antibody (Ab40) 
(Fig 20). The result of the staining confirmed the absence of the transgene 
1    2    3     4     5     6     7     8     9     +M
F
 
Northern blot applying a radioactive randomly labelled probe using the 
seladin-1 as template was performed to detect the 
seladin-1 trangene; Lane +: positive control using the original plasmid.  
igure 18 Screening of seladin-1 trangenic mice using PCR 
Screening of the F1 generation of trangenic mice line containing human seladin-1 gene 
using PCR. M: marker 1kB DNA ladder marker ; lanes 2, 4, 5, 8, 9 PCR positive mice for 
Human seladin-1 cDNA was used as positive control. All the positive mice 
detected on the DNA level were negative for mRNA in the Northern blot, 
suggesting that the trangene is not transcripted (Fig 19a). A Western blot 
conclued that the mice did not express the exogenous seladin-1, although the 
+        2       4       5       8       10
.6kb
a
64kDa
55kDa
2 4
seladin-1 negativebPositive for seladin-1 PCR
-
Figure 19 Northern blot and Western blot of transgenic seladin-1 mice 
Northern blot of the
positive control us
 PCR positive mice (2,4,5,8,10). No bands are visible at the size of the 
ing the human seladin-1 cDNA as template. None of these mice show 
expression of the transgene at the mRNA level (a). Western blot probed with anti seladin-1 
specific antibody (b). 40µg total protein was loaded per lane. No differencies were found 
between seladin-1 PCR positive mice and wildtype mice. These data suggest that seladin-
1 mRNA and protein is not present in the transgenic mice. 
1
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M     1     2     3     4     5     6     7     8    +      -
Figure 21 Screening of seladin-1 HA trangenic mice using PCR 
PCR screening of the F1 generation of transgenic mice containing human seladin-1 gene 
tagged with an haemagglutinin sequence at the 3’ end. M: marker 1kB DNA ladder marker 
lanes 2, 3, 4, 6, 7 PCR positive mice for seladin-1(HA) transgene; Lane +, -: positive and 
negative control, respectively. 
positive for
seladin-1 PCR
observed in the Northern blot. In light of these accumated negative data we 
concluded that these mice did not express the transgene and therefore were 
not further investigated. 
 
cortex                       hippocampus                 cerebellum
wildtype
 
Generation of a seladin-1 (HA) overexpressing mouse line 
To generate seladin-1 (HA) overexpressing mice, the cDNA of human seladin-
1 containing an HA tag at the 3’ end was cloned into the BamHI/XhoI site of 
Figure 20 Cryosections of seladin-1 transgenic mice stained with anti Ab40 antibody 
Immunohistochemistry of brain sections of wildtype and seladin-1 PCR positive mice. Staining 
with the anti seladin-1 specific antibody (Ab40) in cortex hippocampus and cerebellum; no 
differencies are visible, suggesting that human seladin-1 protein is not produced although the 
mice were PCR positive for the trangene.  
  73 
 
R
E
S
U
L
T
S
ne by PCR of mouse tail genomic DNA using the 
ame primers. The construct was sequenced to confirm the presence of the 
HA tag in frame at the 3’ end of the seladin-1 cDNA. Several mice were found 
a
the plasmid pEX-12. Expression of the transgene was under control of the 
neuronal mThy1.2-promoter. Mice were tested as previously described for the 
presence of the transge
s
PCR positive (Fig 21).  
This finding lead us to the next step in the characterisation of the mouse line 
performing a Western blot. However, 
250
148
98
64
50
36
22
sel wildtype
C   Cer C   Cer
β-actin
sel
Figure 22 Western blot of seladin-
1(HA) transgenic mice probed with 
anti HA antibody 
Western blot of seladin-1(HA) and 
wildtype mice probed with anti 
haemagglutinin antibodies. No HA 
staining was detected suggesting that 
the transgene was not expressed. The 
β-actin band shows that the same 
amount of total protein was loaded. 
the membranes probed with anti-HA 
ntibodies did not reflect the result found in the DNA level (Fig 22). 
cortex                    hippocampus                  cerebellum
positive for
seladin-1 PCR
wildtype
Fig
Im
between the transgenic and the wildtype mice were detected. 
ure 23 Paraffin sections of seladin-1 transgenic mice stained with anti HA antibody 
mmunohistochemistry of brain sections of seladin-1(HA) and wildtype mice. No differencies 
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Generation of a seladin-1 EGFP overexpressing mouse line 
 the presence of the EGFP tag in frame at 
th A. Mice were genotyped as previously 
described for the presence of the transgene by PCR of mouse tail genomic 
D signed to cover the 3’end of seladin-1 
containing the EGFP-tag with the forward primer 
(pSelEGFP,R1:CTTGAACACCACCCAGG) and the 5’ end of the PrP-MO 
characterized the PCR positive mice using Western blot and 
immunohistochemical analyses as described above. No seladin-1 transgene 
could be detected in these mice. Based on the fact that in both cases the 
results were negative we concluded that also in this case the transgenic 
mouse lines produced were useless.for our prupose. 
To generate mice overexpressing seladin-1 EGFP, the human seladin-1 
cDNA was fused to an enhanced green fluorence protein (EGFP) tag at the 
3’end cloned into the XhoI site of the plasmid PrP-MO. Expression of the 
transgene was under the control of the neuronaly active PrP-promoter. The 
c
Furthermore, immunohistochemical staining (Fig 23) revealed no differences 
between the seladin-1(HA) and the wildtype mice. These last data conducted 
us to discard the second trangene defining as unserviceable for our 
proposition. 
 
onstruct was sequenced to confirm
e 3’ end of the seladin-1 cDN
NA. The primers used were de
plasmid with a complementary reverse primer (Prp3(5-3): 
GGTTCTCATTCTTGCTTCTC). The PCR revealed some positive mice, 
confirming the introduction of the transgene into the genome (Fig 24). We 
M   1   2    3    4   5   6   7   8   9   10  11   +   -
Figure 24 Screening of seladin-1 EGFP mice using PCR 
PCR pictures using primer on seladin-1 EGFP tagged cDNA and the plasmid PrP-MO. M: 
2 log marker; lane 3, 6, 8, are PCR positive mice for human seladin-1 cDNA; lane + and –
are positive and negative controls, respectively. 
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eve and colleagues identified seladin-1, the sel
Discussion 
 
Anti apoptotic function of seladin-1  
In 2000, Gre ective Alzheimers 
disease indicator-1, a protein that shares domain homologies with a gene 
family of FAD-depe
endogenous seladin-1 was associated with resistance against Aβ-induced 
 
nd a decrease in the 
tr  
in iption was inversly associated with 
ndent oxidoreductases. This study showed that seladin-1 
mRNA was highly expressed in neuronal cells throughout mammalian brains, 
and its expression was low in neurons within selectively vulnerable regions of 
AD brains5. Reduced levels of seladin-1 mRNA in affected areas of AD brains 
were related to reduced amounts of seladin-1 mRNA within remaining 
neurons and did not simply reflect neuronal cell loss. Reduced brain tissue 
levels of seladin-1 mRNA were paralleled by reduced levels of seladin-1 
protein in affected regions. The reduced expression of seladin-1 in vulnerable 
brain regions in AD is in line with results of previous studies on antioxidant 
enzyme activities in AD brains; the activities of catalase and superoxide 
dismutase in temporal cortices from AD brains were lower when compared 
with temporal cortices from non-demented normal controls148. Differential 
activity of antioxidant enzymes in nerve cell populations may be one important 
cause for the selective resistance of specific cells against degeneration by 
toxic factors such as Aβ, which is distributed throughout the brain in both 
vulnerable and protected regions. Previous experiments showed that 
overexpression of seladin-1 in human H4 neuroglioma cells protected these 
cells from apoptosis induced by oxidative stress, and high expression of 
toxicity. Moreover, functional expression of seladin-1 in H4 cells resulted in 
the inhibition of caspase-3 activation after either Aβ-mediated toxicity or
oxidative stress and protected the cells from apoptotic cell death. In apoptotic 
cells, however, endogenous seladin-1 was cleaved to a 40 kDa derivative in a 
caspase-dependent manner5. In 2002, Iivonen and colleagues studied the 
relative transcription of seladin-1 in temporal and occipital cortices in 
demented and non-demented subjects and fou
anscription of seladin-1 in temporal cortex when compared to occipital cortex
 AD123. Moreover, the seladin-1 transcr
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ddition, these authors 
investigated the changes in seladin- 1 transcription in relation to amyloid 
accumulation and aging using a transgenic mouse model of AD. Results from 
these studies revealed that the transcription of mouse seladin-1 fluctuates 
during aging and this fluctuation was enhanced in double APP/PSEN-1 
transgenic mice123.  In 2004, Wu et al. identified seladin-1 as a key mediator 
of Ras induced senescence1. Activated Ha-RasV12 (Ras) is usually 
associated with cancer, but it also produces paradoxical premature 
senescence in primary cells by inducing reactive oxygen species followed by 
accumulation of tumour suppressors p53 and p16INK4a149. They found that 
following oncogenic and oxidative stress, seladin-1 binds p53 amino terminus 
and displaces E3 ubiquitin ligase mdm2 from p53, thus resulting in p53 
accumulation. Additionally, seladin-1 was shown to cause the bypass of Ras-
induced senescence in rodent and human fibroblasts, and allowed Ras to 
transform these cells. Wildtype seladin-1, but not its mutant form disrupted the 
association with p53 and suppressed the transformed phenotype. The same 
mutants were also inactive in directing p53-dependent oxidative stress 
response. These results determined an additional role for seladin-1 in 
integrating cellular response to oncogenic and oxidative stress. We 
overexpressed wildtype seladin-1 in human neuroblastoma SH-SY5Y cells 
and consistent with previous findings5, these cells revealed a greater 
resistence against oxidative stress induced by H2O2. We also analyzed the 
two additional cultures, which carry point mutations in the seladin-1 construct 
at the presumed cleavage sites of either caspase-3 or caspase-6 (474 and 
1256 cultures) respectively. These mutations were proposed to block the 
caspase activity. Our results, after inflicting oxidative stress, show that the 
expression of wildtype or 474 mutated seladin-1 significantly protects the cells 
against H2O2 toxicity, whereas the 1256 mutation did not confer greater 
resistance to the cells. The point mutation at the 1256 position is located in 
the p53 binding site of the protein1. Therefore it is possible that an amino acid 
substitution in this region prevents p53 binding and defeats the anti apoptotic 
function of the protein. This explanation is supported by the fact that the 
survival of 1256 culture did not show any statistical differences compared to 
control cells.  
neuritic plaques and neurofibrillary tangles. In a
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Depending on the apoptotic inductor utilized, various me
volved in the apoptotic cell death. While H2O2 induces oxidative stress in a 
general manner, etoposides block the top
chanisms are 
in
oisomerase II activity, an enzyme 
crucial for DNA replication. 14 hours after etoposide treatment seladin-1 
overexpressing cultures exhibited a significantly larger number of surviving 
cells than the control cultures. In this experiment, the surviving rate of the 474 
culture was smaller compared to the wildtype seladin-1 overexpressing cells, 
but more cells survived the insult when compared to control cells, even if not 
statistically significant. Independent of the apoptotic insult, the percentage of 
surviving cells in the 1256 culture was similar to those in the control cultures, 
suggesting that this mutation affected the anti-apoptotic function of seladin-1. 
All cell lines were non clonal lines with different percentages of transfected 
cells stably expressing the transgene. In the seladin-1 overexpressing culture 
30% of the cells overexpressed the transgene, whereas in the 474 and 1256 
cultures only 22% and 16% of the cells were shown to express the transgene 
on IHC level, respectively. The seladin-1 overexpressing culture consistently 
appeared to be the most robust and fastest growing culture, whereas 474 
cells also seemed to proliferate more rapidly than the 1256 and the control 
cultures. These data are in agreement with published results, showing an anti-
apoptotic and growth promoting role for seladin-11,150. Resistance of cultured 
cells to Aβ toxicity was previously found to be attributable to the transcriptional 
activation of antioxidant enzymes, including glutathione peroxidase or 
catalase78,151. Greeve et al. extended that proposal by adding seladin-1, which 
may function in concert with these enzymes in protecting cells from oxidative 
stress and Aβ toxicity. In our system, the overexpression of neither wildtype 
nor mutated seladin-1 in SH-SY5Y cells resulted in a significantly higher 
resistance against Aβ induced toxicity when compared to control cells. A 
general trend, however, was observable, suggesting that a smaller number of 
cells underwent apoptosis in seladin-1 and 474 cultures. In an additional 
experiment we could show that the endogenous level of seladin-1 in wildtype 
SH-SY5Y cells was upregulated after induction of apoptosis. These results 
are consistent with previous observations, where seladin-1 transcription was 
found to be up-regulated in mouse N2a cells induced to undergo apoptosis 
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with okadaic acid123. Taken together, we conclude that seladin-1 has an anti-
apoptotic role in vitro. It is upregulated by apoptotic stimuli and protects the 
cells against apoptotic cell death induced by different inductors. 
Intracranial injections of seladin-1 overexpressing cells in c57Bl/6 mice were 
performed to examine the effect of elevated seladin-1 levels on cell survival in 
vivo. Earlier studies showed that seladin-1 is upregulated in different types of 
tumors: Expression analysis in benign functioning adrenocortical adenomas 
reveal that seladin-1 mRNA was overexpressed in the adenoma tissue of 14 
patients with Cushing’s syndrome in comparison to the adjacent nontumorous 
adrenal gland150. Di Stasi et al. found an elevation of seladin-1 gene 
expression in melanoma metastases that was associated to resistance to 
oxidative stress-induced apoptosis152. Given that seladin-1 overexpression 
can protect cells against apoptosis in vitro, we tested whether seladin-1 could 
also be protective under conditions, where external physiological factors (i.e. 
components of the immune system) are the inductors of the apoptotic insults. 
We expected that seladin-1 overexpressing SH-SY5Y cells are more resistant 
against the defensive mechanisms of the murine host. Eventhough the 
survival of seladin-1 oveexpressing cells was higher four days after 
implantation, tumors has developed equally four weks later. We could not 
detect any apparent differences in tumor growth or profile between seladin-1 
overexpressing and control SH-SY5Y cells. Because the brain is an immune-
privileged organ, this can be explained by the fact that the immunosystem of 
the brain might not be potent enough to protect the host against extraneous 
cells that are thoroughly immortalized. In this scenario the surviving rate of the 
injected SH-SY5Y cells would be independent of seladin-1 overexpression, 
since there is no requirement for an anti-apoptotic function. With our 
experiments it still remained elusive as to which role seladin-1 plays in terms 
of oncogenic signaling and Ras-induced senescence. Wu and colleagues in 
2004 could show that injections of seladin-1 deficient fibroblasts with depleted 
seladin-1 expression in immuno-suppressed nude mice resulted in tumorous 
proliferation of the cells two weeks after inoculation, indicating that they were 
oncogenically transformed1. In contrast, cells with normal levels of seladin-1 
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failed to proliferate as tumours. This observation is somehow contradictive to 
previous findings, where seladin-1 was hightly upregulated in tumor cells152. 
 
Production of a mouse model overexpressing seladin-1 
Based on our findings concerning the role of seladin-1 in vitro and in vivo we 
next tried to generate mice overexpressing seladin-1 to study the effect of 
seladin-1 overexpression in vivo. To achieve our goal we encountered a 
sequence of problems which we are trying to solve. All experiments of 
determining a transgenic overexpression led to negative results indicating that 
the seladin-1 transgene was not expressed in these mouse lines even though 
PCR screenings for detection of the insertion of the transgene were positive. 
The reason for lack of transgenic expression were not further investigated. 
Results from our laboratory show that the promoters used  (mThy1.2 and PrP) 
are functional, because they drive the expression of other transgenes in 
transgenic mice48,61. Seladin-1 is normally expressed in all brain neurons. To 
avoid the possibility to miss low levels of transgene expression in neurons of 
our mice we also tried to generate mouse lines expressing an HA-tag or 
EGFP fused to the seladin-1 cDNA. Again, no transgene expression could be 
found in these mice. The lack of transgenic seladin-1 expression in these mice 
led us to speculate that an elevation of seladin-1 levels during neurogenesis 
can not be tolerated, probably because of the interferance with normal 
elimination of excessive neurons of with cholesterol metabolism. Therefore, 
we are now trying, as a last resort, to use a tet-on system to be able to switch 
on the expression of seladin-1 in neurons at an adult age, thus eliminating a 
possible obstruction of seladin-1 function in neuronal development. 
 
The role of seladin-1 in cholesterol biosynthesis, raft composition 
and function, Aβ generation and AD pathology 
Desmosterolosis is a rare autosomal recessive disorder characterized by 
multiple congenital anomalies. Patients with desmosterolosis have elevated 
levels of the cholesterol precursor desmosterol, in plasma, tissue and cultured 
cells. The only two known patients homozygous for these mutations died 
shortly after birth and in early childhood125.  
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with the C2 
environement. They are highly loaded with glycosphingolipids, choelsterol and 
In 2001, Waterham et al. published that this abnormality suggested a 
deficiency of the enzyme 3β-hydroxysterol∆24-reductase (DHCR24), also 
named seladin-1. Isoprenoid/cholesterol biosynthesis starts 
compound acetyl-CoA, which, in a series of different enzyme reactions, is 
converted to isopentenyl-pyrophosphate, the basic C5 isoprene unit used for 
the synthesis of all subsequent isoprenoids153,154. The first intermediate 
committed to the production of sterols is C30 squalene, which is converted to 
lanosterol. To eventually produce cholesterol from lanosterol a series of 
enzyme reactions is required. Consequently, two major routes involving the 
same enzymes have been proposed, the Bloch synthesis pathway with 
desmosterol as the ultimate precursor of cholesterol and the Kandutsch-
Russell pathway with 7-dehydrocholesterol as the direct precursor. Seladin-1 
is crucial for cholesterol biosynthesis, as it is the mediating enzyme between 
the two pathways – reducing the ∆24 double bond of the bloch-pathway 
precursors to finally produce cholesterol. Bloch synthesis occur principally 
during the development and at young age, whereas the Kandutsch-Russell 
pathway is active in adulthood. 
Sterol analysis in seladin-1 overexpressing SH-SY5Y cells revealed 
dramatically reduced desmosterol levels and significantly elevated membrane 
and cellular cholesterol levels when compared to control cells. These results 
gave evidence for the bioactivity of the transgene and suggested that seladin-
1 is the limitting factor in modulation and regulation of cholesterol 
biosynthesis.  
Cholesterol is a prominent modulator of the integrity and functional activity of 
physiological membranes - and hence plays an essential role in the regulation 
of synaptic function and membranous signal transduction pathways. Within 
the plasma membrane, cholesterol is strictly organized into structual and 
kinetic pools such as leaflet domains and lipid rafts155. Lipid rafts are 
specialized plasma membrane micro-domains, so called detergent resistant 
membrane domains (DRMs of rafts), floating on the exofacial side of the 
membrane bilayer156. Regarding their physicochemical and structural 
characteristics, they clearly differ from the adjacent non-raft lipid 
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iochemical analysis of DRMs prepared from seladin-1 overexpressing SH-
SY5Y cells revealed a
holesterol resulted in increased membrane fluidity and shifted APP 
processing to
studies was that lowering chole
β-cleavage and 
multiple membrane proteins and play a crucial role in cell-signaling 
pathways157. 
B
 significant change in raft composition and function. 
DRM specific proteins (like PrPc and flotilin 1), and lipids (like cholesterol, 
sphingomyelin and the ganglioside GM1) also showed elevated levels in the 
fractions corresponding to DRMs when compared to control cells. Co-patching 
experiment revealed that the size of DRMs in seladin-1 overexpressing cells 
was greater than in control cells. These data imply that the composition of 
rafts is determined by the amount of membrane and/or cellular cholesterol and 
that the expression level of seladin-1 can modulate these cholesterol 
concentrations and therefore determine raft composition and size. Functional 
analysis revealed a higher plasmin activity in seladin-1 overexpressing cells 
and the ability of plasminogen to bind to the membrane was significantly 
increased in these cells. These results suggest that the amount of cholesterol 
in a membrane determines not only the composition and the size of DRM’s 
but also their functional properties.  
 
A large body of literature indicates that alterations in cholesterol levels affect 
APP metabolism. The two important enzymes involved in amyloidogenic APP 
processing, BACE and the γ-secretase, were found to reside within DRMs of 
the late Golgi and endosomes158. APP, however, is found exclusively in non-
raft membrane compartiment. Whether the membrane or cellular cholesterol 
levels play the crucial role in affecting APP processing has not yet studied to 
date in vivo. Serveral studies in the last years could show that reducing 
c
ward the APPsα pathway. The common observation in these 
sterol levels resulted in a strong decrease in 
Aβ production159,160. Others proposed that lipids, by participating in producing 
raft domains, might build an invisible boundary, corralling the γ-secretase 
complex and BACE away from their substrate, APP. Their surveillance was 
that moderate lowering of cholesterol led to an increased 
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-processing, as was shown in a cell culture 
e mice, however, were dramatically smaller in size and 
elevated Aβ levels in primary neuronal cultures.145 Consistently, these 
alterations also resulted in diminished activity of the Aβ degrading enzyme 
plasmin, which is normally produced in these domains161. Our data revealed 
clearly that APP processing was affected in seladin-1 overexpressing cells. 
We found reduced β-CTF generation in seladin-1 overexpressing cells that 
exhibited elevated cholesterol concentrations and the production of Aβ was 
significantly decreased in these cells when compared to control cells.  
These findings are consistent with the hypothesis that elevated cholesterol 
levels and therefore greater DRMs immobilize the β-secretase within the lipid 
rafts and prohibit its interaction with APP leading to a decrease in β-cleavage 
of APP, an integral membrane protein that does not reside within rafts. We 
therefore put forward the idea that BACE1 in cholesterol-rich raft domains 
may represent an inactive pool of the protein, at least in terms of APP 
cleavage, which can be delivered when required to soluble domains where 
APP resides. In support of this view, a mild reduction of membrane cholesterol 
results in more BACE1 in the soluble fractions, higher BACE1-APP 
colocalization and enhanced β
system145. 
The seladin-1 knock-out mice were published in december 2003 by Wechsler 
and co-workers. These mice are viable even though almost no cholesterol 
was found in plasma and tissue of three months old knock-out mice94. In our 
colony, homozygous mice were born to the published frequency of about 
15%, but thes
extremely weak under normal husbandary conditions, and most of them died 
before reaching  the age of 3 weeks, probably because of the inconsistency of 
vertebrate life with total lack of cholesterol or due to insufficient maternal care. 
The heterozygous knock-out mice in our colony developed normally and had 
no problem of health, fertility or longevity (up to 16 months). In this study we 
sacrificed the only two seladin-1 knock-out mice that were born in our colony, 
three weeks after birth and compared them to their heterozygous and wildtype 
littermates. We found a gene-dose dependent effect: The heterozygous mice 
exhibited a 50% reduction of seladin-1 expression on mRNA level. In the 
knock-out mice, seladin-1 expression was abolished. Next, we could show 
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vels and cholesterol homeostasis in the mouse brains: In 
leads to an increased β-cleavage of 
ansgenic APP and therefore resulting in elevated Aβ levels in these mice 
that develop the first Aβ deposits as early as 6 months after birth in the 
of
40 42 
that modulated seladin-1 expression influeced membrane and cellular 
cholesterol le
seladin-1 knock-out mice cholesterol undetectable. As a consequence of 
abolished seladin-1 expression, desmosterol was not sufficiently catabolized 
in these mice, resulting in vast amounts of the accumulated choelsterol 
precursor in knock-out brains. According to the negligible levels of cholesterol, 
only minor concentrations of the oxysterol 24OH-cholesterol was detected in 
the knock-out mice. Heterozygous mice with 50% less seladin-1 expression 
exhibited a significant reduction of membrane and cellular brain cholesterol, 
and considerablely elevated concentrations of desmosterol. In addition, a non-
significant reduction of the catabolic product 24OH-cholesterol was observed 
in brains of heterozygous mice. Regarding the findings that overexpression of 
seladin-1 led to decreased Aβ production in our study and taking into account 
that the reduction of cholesterol in vitro resulted in increased Aβ generation as 
previously demonstrated145, we crossed the seladin-1 deficient mice with 
mice, overexpressing the human APP carrying the Swedish (Sw) mutation 
(SwAPP mice)162. This mutation 
tr
cerebral cortex. As expected, no seladin-1 knock-out mice survived, 
overexpressing the SwAPP. Probably vbecause of an additive effect of 
seladin-1 knock-out and Sw mutation. Nevertheless, we could show for the 
first time, that the depletion  seladin-1 in heterozygous knock-out mice 
overexpressing SwAPP results in increased brain amyloidogenic APP 
processing and in significantly augmented Aβ40 and Aβ42 generation when 
compared to wildtype seladin-1 SwAPP mice. Because seladin-1 is down-
regulated in vulnerable areas of brains in AD patients 5 it is reasonable to 
think that low levels of seladin-1, promoted by yet to be identified causes, are 
responsible for the membrane cholesterol reduction found in such brains144. 
This would consequently lead to Aβ accumulation via a combination of 
increased APP amyloidogenic cleavage and possibly reduced activity of Aβ 
degrading enzymes like plasmin. Moreover, the observation of unchanged 
ratios of Aβ  and Aβ levels supports the involvement of a BACE-mediated 
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ay be 
β was reduced in seladin-1 overexpressing cells and 
increased in seladin-1 deficient mouse brains. These findings promote a new 
mechanism. Furthermore, our data of a reduction of cholesterol catabolites in 
seladin-1 deficient mouse brains are supported by a study showing that 
cholesterol degradation products, especially 24OH-cholesterol, inhibit the 
production of Aβ in neurons by a liver-X-receptor (LXR) dependent 
mechanism163. 
In conclusion, our results establish a role of seladin-1 in the formation of 
DRMs and suggest that seladin-1-dependent cholesterol synthesis m
involved in lowering Aβ levels. Furthermore, pharmacological increases in 
seladin-1 activity may be a novel Aβ-lowering approach for the treatment of 
AD. 
 
 
Outlook 
In conclusion, our results show that seladin-1 plays an important role in 
apoptosis and in cholesterol metabolism in vitro and in vivo. The link to AD 
was found in the ability of seladin-1 to regulate DRM composition and function 
via cholesterol. A
cholesterol based mechanism, which propose the membrane cholesterol as a 
essential factor to prevent AD. Further studies must clarify the implication of 
seladin-1 in NFT formation and neurodegeneration. Overexpressing seladin-1 
in animal models will advance our understanding of the roles of seladin-1 and 
identify potential disease-modifying factors in AD. Studies of knock-out and 
overexpressing seladin-1 mice will also provide novel strategies for the 
treatment and prevention of AD and related disorders. 
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Materials 
 
Solutions 
Blocking buffer 
1x PBS 
5% Horse serum 
0.05% Triton X-100 
 
Coomassie staining solution 
0.16%(w/v) coomassie Blue R250 
40%(v/v) methanol 
10%(v/v) acetic acid 
 
Coomassie destaining solution 
45%(v/v) methanol 
10%(v/v) glacial acetic acid 
 
Culturing DMEM-F12 medium 
2mM L-glutamine  
1 mM sodium pyruvate 
10% fetal calf serum (FCS) 
5% horse serum (HS) 
5 U/ml penicillin  
50µg/ml strepavidiC 
 
DEPC-H2O 
0.2 ml DEPC  
100 ml H2O 
stir under a fume hood overnight 
autoclave 
 
DNA sample buffer 
0.25%(w/v) bromophenol blue 
0.25%(w/v) xylene cyanol FF 
30%(w/v) glycerol 
Extraction buffer (rafts prep) 
25mM MES pH=7.0 
5mM DTT 
2mM EDTA 
 
 
Formaldehyde Gel  
1% agarose 
7% formaldehyde 
 
Hybridization Wash-buffer 
0.25 M Na2HPO4 (pH 7.2)  
1 % (w/v) SDS  
1 mM EDTA 
 
Ketalar/Rompun 
Ketamin 12.5mg/ml 
Xylazin 2.5mg/ml 
in PBS 
peritoneally injected: 8µl/g mouse 
 
LB agar 
LB medium 
15g/L Bacto Agar 
 
LB medium 
10g/L Bacto Tryptone 
5g/L Bacto Yeast extract 
10g/L NaCl pH=7.0 
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Lo
10
0.
0.
50 + EtBr 
 
ading buffer 6x 
mM EDTA, pH 8.0 
25% (w/v) bromphenol blue 
25% (w/v) xylene cyanol 
% (v/v) glycerol
MOPS running buffer 10x 
0.2 M MOPS [ 3-(N-morpholino)- 
propanesulfonic acid] (pH 7.0) 
0.5 M sodium acetate 
Lo
1x
50
6.6% formaldehyde 
 
ading buffer 2x (NB) 
 running buffer 
% deionized formamide 
 
NuPage running buffer 20x 
1M MOPS 
1M Tris-Base  
Loading buffer 4x (WB) 
100 mM Tris-Base 
100mM Tris-HCl  
4 
40
0.
0.
0.
1.
 
% (v/v) ß-mercaptoethanol 
 % (v/v) glycerol 
08 % (w/v) serva blue G250  
025 phenol red  
6‰ EDTA  
92 M glycine 
sis buffer 
7mM NaCl 
mM Tris pH=7.6 
 Triton X-100 
4g PFA 
few drops NaOH till clear 
up to 1 litre pH=7.4 
 
PBS 1x 
8g  NaCl 
0.2g  KCl 
0.2g  KH2PO4 
0.765g Na2HPO4*2H2O 
Adjust  pH to 7.4 
up to 1 liter 
 
Permeabilizit
Ly
13
20
1%
25x protease inhibitors 
 
MBS for sucrose gradient 
25mM MES pH=7.0 
150mM NaCl 
add (w/v) sucrose for  
90%, 35%, 5% 
 
 
ion buffer 
1x PBS 
0.1% Triton X-100 
25x proteinase inhibitors 
 
Ponceau S solution 
0.2%(w/v) Ponceau-S red 
3%(w/v) sulfonic acid 
0.1%(v/v) glacial acid 
69.3 mM SDS 
20.5mM EDTA 
 
Paraformaldehyde (PFA) 4% 
Heat ddH2O 200ml 65°C 
0,01 M EDTA 
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Protein sample buffer 2x 
450mM Tris-HCl pH=8.45 
12%(v/v) Glycerol 
4%
7.5‰  Coomassie brillant Blue 
2.
TAE Buffer 50X 
242 gr. Tris 
57.1 ml glacial acetic acid 
(w/v) SDS 
5‰ Phenol Red 
 
RNA sample buffer 6x 
10
0.
0.25%(w/v) xylenecyanol 
50
 
mM EDTA pH=8 
25%(w/v) bromphenol blue 
%(v/v) glycerol 
SS
17
88g (tri-)Sodium Citrate Dihydrate 
900 ml H2O 
Ad
up
 
C 20x 
5g NaCl 
just pH=7.0 with HCl 
 to 1 litre 
SS
3M
0. 20  
20
adjust pH to 7.4 with NaOH 
 
PE 20x 
 NaCl  
2 M NaH2PO4 x H
 mM EDTA  
Stripping solution                         
(fo  
Tris 62.5 mM pH=6.7 
β 
SD
30’ 56°C 
 
 
r WB membrane)
mercaptoethanol 100mM 
S 2% 
100 ml 0.5 M EDTA pH=8.0 
up to 1 litre 
 
TBS (Tris Buffered Saline) 10x  
5 mM Tris 
.8% NaCl 
pH 8.0 
2
0
 
Transfer buffer 10x 
.192 M glycine  
25 mM Tris  
0
20 % (v/v) methanol 
1% (w/v) SDS 
 
Freezing medium 
MEM-F12 
 
D
20 % (v/v) FCS 
5% HS 
10 % (v/v) DMSO 
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smids 
 
In
Pla
pcDNA3+ (CMV promoter) vitrogen 
pEX-12 (mThy1.2 promoter) Kusters JG164 
pPrP-MO (PrP promoter) rchelt DR165 Bo
pSFV2gen Life Technologies166 
pSFVHelper  Li  fe Technologies
Antibodies 
tibodies 
 
40  
 
c
LabForce 
anta Cruz 
Santa Cruz 
Sigma 
Roche 
Takeda 
Takeda 
Takeda 
mith Kline 
Sigma 
Nano-tools 
Nano-tools 
A.Aguzzi Zürich 
tion Laboratories 
anta Cruz 
Signet 
 
Primary  an
Annexin-V-FITC (direct conjugated) 
Anti HA (rat) 
Anti HA (mouse) 
Anti APP C-terminal (rabbit) 
Anti APP N-terminal (mouse) 
Anti Aβ(40,42) (BNT77)
Anti Aβ  HRP (BA27)
Anti Aβ42 HRP (BC05)
Anti BACE1 (rabbit) 
Anti MAP-2 (mouse) 
Anti seladin-1 N-Terminal (rabbit) 
Anti seladin-1 C-Terminal (rabbit) 
Anti EGFP (rat) 
Anti PrP  POM-1 (mouse) 
Anti Flotilin 1 (mouse) 
Anti Transferrin Receptor (mouse) 
6E10 
S
C.Dingwall Glaxo S
Santa Cruz 
Transduc
S
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antibodies 
 FITC 
Anti rabbit FITC 
 Cy5 
 TRITC 
t TRITC 
Amersham 
Pierce 
rsham 
Alexia 
Alexia 
 
Jackson 
Jackson 
Alexia 
Secondary conjugated 
Anti mouse-HRP 
Anti rabbit HRP 
Anti rat HRP Ame
Anti mouse
Anti rat FITC Alexia
Anti mouse
Anti rabbit
Anti ra
 
Primers 
Pr leavage site mutations imer for caspase c
primer name aim 5’→3’ 
Sel1F,D474E,gaC→gaA site mutation of 
Caspase-3 cleavage  
GGA CAT TCT GGA AGT GGA AAC 
GT CCG CAA GAa ACA GAT T
Sel1R,D474E,ctG→ctT site mutation of 
Caspase-3 cleavage  
TC TGT TTC TTG GTT 
A ATG TCC 
CGG ACA A
TCC ACT tCC AG
Sel1F,D1256E,gaC→gaA site mutation of 
Caspase-6 cleavage  
GT GGT GCA GGA AAT GCT 
 GTG CC 
CCA C
GGT GCC CAT GAa
Sel1R,D1256E,ctG→ctT site mutation of 
Caspase-6 cleavage  
GGC ACT tCA TGG GCA CCA GCA 
TTT CCT GCA CCA CGT GG 
Primer for desmosterolosis mutations 
5’→3’ primer name aim 
Sel1F, A to C mutation
N294T 
 Desmosterolosis 
mutation 
AGA GCC CAG CAA GCT GAc TAG 
CAT TGG C 
Sel1R, A 
N294T 
to C mutation Desmosterolosis 
mutation 
GCC AAT GCT AgT CAG CTT GCT 
GGG CTC T 
S
K
el1F,G to C mutation  
306N 
Desmosterolosis 
mutation 
CAA GCC GTG GTT CTT TAA cCA 
TGT GGA GAA C 
S
K
el1R,G to C mutation  
306N 
Desmosterolosis 
mutation 
GTT CTC CAC ATG gTT AAA GAA 
CCA CGG CTT G 
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el1F,G to A mutation 
E191K 
Desmosterolosis 
mutation 
TCT GCA CTG CTT ACa AGC TGG 
TCC TGG CTG 
S
Sel1R,G to A mutation 
E191K 
Desmosterolosis 
mutation 
CAG CCA GGA CCA GCT tGT AAG 
CAG TGC AGA 
 
Primer for HA tag in human seladin-1cDNA insertion 
Primer HA F sel1 for HA tag CAA GCT GGT ACC GAG CTC G 
Primer HA R sel1 for HA tag A GCC TCT AGA AGC TCG AGC TCA 
 AAC ATC GTA TGG 
GTA GTG CCT GGC GGC CTT GC
AGC GTA ATC TGG
A G 
Primers for sequencing  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
l1 GG ACA TCC AGAprimer2,F,se  AGC A 
GA TCA A 
primer3,F,sel1 CGT GTT GCC TGA GCT T 
primer3,R,sel1 TGA ACT TGG CAC AGA T 
TCG AG 
 TGC T 
ATT CCC TTG AGA CAC T 
GA T 
primer6,F,sel1 CCT GCA CAC CTT CCA A 
AA ACA T 
primer7,F,sel1 GTA TGC CGA CTG CTA C 
primerT7,R,sel1 CAC GGC GGG CTC CAT 
primer2,R,sel1 CTG TGC CCA T
primer4,F,sel1 TCA AGC TGC GTT 
primer4,R,sel1 GCT CCC AGA AGA
primer5,F,sel1 
primer5,R,sel1 ACG GAC ACA GCC A
primer6,R,sel1 AGG AGC CAT C
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  product  any 
ABI Prism 310 Genetic Analyzer  Applied Biosystems 
Devices and Chemicals 
   comp
ABI Prism 7700 Sequence Detector Applied Biosystems 
Centrifuge 5417C  eppendorf 
Centrifuge 5417R  eppendorf 
Concentrator 5301  eppendorf 
Gel Dryer Model 583  BioRAD 
Gene Pulser II Electroporation 
System  
BioRAD 
Gene Quant pro (Phot er)  Amersham Pharmacia omet
GeneAmp PCR System 9700  PE Applied Biosystems 
MP 220 pH Meter  Mettler Toledo 
Horizontal Electrophoresis System  owl 
Leica DMRXE  Leica 
Leica RM 2135  Leica 
RoboCycler Gradient 96  Stratagene 
Rotor GSA 
β-mercaptoethanol  Sigma 
10-20% TrisTricine gels  Novex 
4-12% TrisTricine gels  Novex 
Biomax MR film  Kodak 
 Sorvall 
Rotor SS-34  Sorvall 
Agarose  Gibco BRL 
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Bromphenol blue  Sigma 
BSA  Sigma 
CaCl2  Sigma 
Calf intestinal phosphatase (CIAP)  Promega 
Cell culture dishes  TTP 
Cell culture flasks  Falcon 
Cell culture media  Gibco BRL 
MercChloroform  k 
Complete Protease Inhibitor  Roche 
Coomassie brilliant blue  k Merc
Sigma
Sigma
New England Biolabs
Roche 
Sigma
Sigm
DEPC   
DMSO   
DNA ladder   
DNase I  
dNTPs   
EDTA  a 
EndoFree Maxi Kit  QIAGEN 
Ethanol  Kantonsapotheke Zurich 
ExpressHyb  Clontech 
FCS  Biochrom KG 
Formaldehyde  Fluka 
Formamide  Calbiochem 
Glacial acid  Merck 
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Glycerol  Sigma 
Glycine  Merck 
Hybond+  Amersham Pharmacia 
Isopropanol / Ketamin Sigma, Streuli Uznach 
LF2000  Invitrogen 
Methanol  Merck 
MgCl2  Sigma 
Milk powder  Migros 
MOPS  Sigma 
MuLV reverse transcriptase  Perkin Elmer 
Na2HPO4  Merck 
NaAc  Merck 
NaCl  Sigma 
NaOH  Sigma 
Nitrocellulose-membrane 0.1µm  Schleicher&Schuell 
Nitrocellulose-membrane 0.45µm  BioRAD 
Oligonucleotides  Metabion 
Microsynth 
Paraformaldehyde  Elctron Microscopy Sciences 
Pfu polymerase  Stratagene 
Phenol  Merck 
Ponceau-S  Merck 
Proteinase K  Roche 
PVDF-membrane  Millipore 
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it  QIQIAGEN DNeasy K AGEN 
QIAGEN Nucleotide Removal Kit  QIAGEN 
QIAGEN PCR purification kit  QIAGEN 
QIAGEN Plasmid Maxi Kit  QIAGEN 
QIAGEN Plasmid Midi Kit  QIAGEN 
QIAGEN RNeasy Kit  QIAGEN 
Rapid DNA Ligation Kit  Roche 
Restriction Endonucleases  New England Biolabs / Roche 
Salmon sperm DNA  Roche 
SDS  Sigma 
T4 DNA ligase  New England Biolabs 
Tricine  Sigma 
Tris  Sigma 
Triton X-100  Sigma 
Trizol  Gibco BRL 
Trypsin/EDTA  Gibco BRL 
Tryptone  Becton Dickinson 
Tween20  Sigma 
Xylazin 
Yeast extract  
Streu
Becton Dic
li Uznach 
kinson 
Kodak X-OMAT 2000 Processor Kodak 
Memmert waterbath Fisher Scientific 
Microtome Leica RM 2135 Leica 
MP 220 pH meter Mettler Toledo 
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pse E800 Nikon Ecli Nikon 
Nikon Eclipse TE300 Nikon 
Nikon TMS F Nikon 
NUAIRE Autoflow CO2 Incubator Inotech 
Rotor GSA Sorvall 
Rotor SS34 Sorvall 
SKAN VSE 2000-120 sterilhood Skan 
Sorvall RC 26 Plus Kendro 
Thermomixer Eppendorf 
Universal 32 Hettich centrifuge Fisher Scientific 
Vibratome Leica VT 1000S Leica 
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Ab ns 
 
aa  amino acids 
brevatio
40aa 
Aβ42 β-amyloid pe
α soluble
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